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Abstract 
 
cAMP and PKA stimulate or inhibit cell proliferation, depending on the cell 
type. For example, cAMP rise induces G1 arrest in NIH 3T3 fibroblast, but it is 
an essential mitogenic signal in TSH-dependent cells. In both cell types, cAMP 
stimulates survival (Affaitati et al., 2003). 
PI3K has been found essential for cAMP induced cell growth and survival 
in many cell types (Rameh and Cantley, 1999), but the exact contribution of 
PI3K signals and the mechanism(s) of actions are still largely unknown. 
 To determine the molecular mechanism(s) linking PI3K to cAMP-PKA, 
we identified and mutagenized a specific serine (residue 83) in p85αPI3K, which 
was phosphorylated in vivo and in vitro by PKA.  
Serine 83 was substituted with alanine (p85A) or aspartic acid (p85D), 
respectively, to abolish or mimic the phosphorylated site. The effects of both 
mutants on cell proliferation and survival were tested both in NIH 3T3 and 
TSH-dependent cells. cAMP protected cells from apoptosis induced by 
substrate detachment (anoikis) or  hormone (TSH) starvation. The expression 
of p85A impaired cAMP mediated cytoprotection and was lethal in thyroid 
cells FRTL5. p85D, on the contrary, amplified and replicated cAMP effects on 
survival.  Analysis of cell cycle progression showed that the phosphorylation of 
the serine 83 mediated cAMP induced G1-arrest in NIH 3T3 and S-G2/M 
progression in TSH-dependent cells.  
These results indicate that phosphorylation of p85αPI3K controls G1 length 
and it is essential for cell cycle progression. The molecular mechanism 
triggering these effects involves : 1. stabilization of the complex Ras-PI3K and 
2. stimulation of PI3K activity. 
The data also shows that the regulatory subunit of PKA, RIIβ, converts 
cAMP from a negative regulator of proliferation (in NIH3T3) to a positive one 
(in endocrine cells). Interestingly, endocrine cells, including thyroid cells, 
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express significant amount of RIIβ. In this context RIIβ binds and targets PKA 
to PI3K and the membrane, stimulating growth and proliferation. 
Moreover, phosphorylation of serine 83 of p85αPI3K is essential also for 
estrogen signaling. p85A expression in MCF-7 impairs the ERα binding to 
p85αPI3K and, as a consequence, abolishes estrogen induced AKT activity. 
Taken together, the data suggests a general mechanism of PI3K regulation 
by cAMP, operating in various cell types under different conditions. 
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 Background 
 
The control of cell growth and survival is a very complex mechanism 
subject to different signals. Each “signaling molecule” (hormones and growth 
factors) interacts with a specific receptor, and this is the first step of the signal 
transduction (Alberts, c2002). 
1. The cellular receptor may be of two types: 
1) Intracellular: typically steroid hormones and small peptides are 
able to diffuse through the plasma membrane and interact with their 
own receptor inside the cells. Usually the complex ligand-receptor 
enters the nucleus and modulates the expression of specific gene 
through the binding to specific responsive elements on the DNA 
(Alberts, c2002); 
2) Extracellular: Most of growth factors, proteic hormones and 
neurotransmitter interact with receptors present on the plasma 
membrane, which can be “tyrosine kinase” or “G protein coupled” 
receptor (Alberts, c2002). 
Briefly, the tyrosine kinase receptors (RTKs) are constituted of two 
subunits, their extracellular domain binds the ligand, while the catalytic 
domain is in the intracellular region. Upon the binding of the ligand this 
receptors dimerize and the tyrosine residues in the catalytic domain 
undergo autophosphorylation. The G protein coupled receptor 
(GPCRs), instead, are characterized by an extracellular domain, seven 
transmembrane segments and an intracellular domain. When the ligand 
binds the receptor it undergoes a conformational change that enables the 
activation of a specific trimeric G protein. The G proteins are 
constituted of three subunits: α, β, γ; in their inactive state the α subunit 
binds GDP. After the binding of the ligand to the receptor the GDP is 
substituted by GTP, the α subunit detaches from the β/γ complex and 
this is the starting point of the transduction pathway in the cell. The 
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GTP is soon hydrolyzed to GDP, and the G protein returns in its 
inactive state (Lodish, c1999 ; Alberts, c2002). 
 
The signal transduced by the receptor is then amplified through a kinase 
cascade inside the cells. 
 
Another important aspect of the signal transduction is that the different 
molecules regulating the cell behavior are not fully independent from the 
others. The activated pathway are overlapping, redundant sometimes and 
linked at many points, they establish a complicate network known as crosstalk. 
An example of crosstalk between receptors is the one between GCPRs leading 
to cAMP increase and RTKs that activate Ras and PI3K. 
 
1. cAMP and Protein Kinase A (PKA) 
GCPRs may bind different kind of G proteins (Table 1), which can act 
through various mechanisms and second messengers (cAMP, Ca2+, inositol 
triphosphate, diacylglycerol or cGMP) (Lodish, c1999 ). 
Specific receptors associated to Gs protein, such as TSH receptor (TSHR), 
activate adenylyl cyclase. This enzyme converts AMP in cAMP that, as a main 
effect, leads to the activation of PKA. PKA is a holoenzyme composed by two 
regulatory (R) and two catalytic subunits (cPKA) (Feliciello et al., 2001, 
2005). cAMP binds to the regulatory subunits leading to the release of the 
catalytic ones, which in turn phosphorylate many nuclear and cytoplasmic 
substrates controlling multiple cell functions, including motility, metabolism, 
differentiation, synaptic transmission, ion channel activities, growth and gene 
transcription (Edelman et al., 1987; Haynes et al., 1992; Meinkoth et al., 1993; 
Feliciello et al., 2001). There are two different types of PKA:  
1) PKA I: it binds the regulatory subunit RIα that has an high 
affinity for cAMP, this entails that it is activated by low level of cAMP; 
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Table 1. Properties of Mammalian G Proteins Linked to GCPRs 
 
Gα 
Subclass* 
Effect Associated Effector 
Protein 
2nd Messenger 
 
Gs  Adenylyl cyclase cAMP 
  Ca
2+ channel Ca2+
  Na
+ channel Change in membrane 
potential 
Gi  Adenylyl cyclase cAMP 
  K
+ channel Change in membrane 
potential 
  Ca
2+ channel Ca2+
Gq  Phospholipase C IP3, DAG 
Go  Phospholipase C IP3, DAG 
  Ca
2+ channel Ca2+
Gt  cGMP 
phosphodiesterase 
cGMP 
Gbγ  Phospholipase C IP3, DAG 
  Adenylyl cyclase cAMP 
A given G  may be associated with more than one effector protein. To date, only one major 
G  has been identified, but multiple G  and G  proteins have been described. In some cases 
(not indicated in this table) effector proteins are regulated by coincident binding to G  and G .
a
sa qa ia
a bg  
KEY: = stimulation; ↓ = inhibition. IP  = inositol 1,4,5-trisphosphate; DAG = 1,2-
diacylglycerol.
3
 
SOURCE: A. C. Dolphin, 1987, Trends Neurosci. 10:53; L. Birnbaumer, 1992, Cell 71:1069. 
(Lodish H., Berk A., Zipursky S.L., Matsudaira P., Baltimore D., Darnell J. Molecular Cell 
Biology New York: W. H. Freeman & Co.; 1999) 
 
2) PKA II: binds the regulatory subunit RII that has a low affinity 
for cAMP; this implies that it is activated by high level of cAMP, 
typically upon Gs activation. Class II of PKA can be further divided 
into two subtypes depending on the kind of RII present in the 
holoenzyme: RIIα or RIIβ. RIIα is ubiquitous (as PKA I), while RIIβ is 
expressed mainly in endocrine, brain, fat and reproductive tissues 
(Edelman et al., 1987; Haynes et al., 1992). Moreover, RIIβ has a 
binding affinity to cAMP lower than RIIα. 
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 2. Ras  
The family of Ras proteins consists of ten highly conserved members, 
among these there are H-, N. and K-Ras, Rap1A and Rap1B. The common 
characteristic of all the proteins belonging to the Ras family is that they are 
small GTP binding protein synthesized in the cytosol, which translocate to the 
plasma membrane once they are activated.  They are activated mainly by 
RTKs. Once the receptor is phosphorylated it recruits an adaptor molecule, 
such as Grb2. The adaptor molecule can bind the P-Tyr of the receptor through 
its SH2 domain and, through its SH3 domain, binds guanine nucleotide 
exchange factor such as SOS, which activate Ras replacing the GDP with the 
GTP.  
The activity of Ras is limited to the time it needs to hydrolyse the GTP to 
GDP, and its GTPase activity is increased, many fold, by another class of 
protein, known as GTPase activating proteins (Kufe, c2003 ). 
 
2a. Pathways downstream of Ras 
The main pathway of Ras is represented by the MAPK (Mitogen Activated 
Protein Kinase) cascade. GTP-Ras binds Raf, a serine-threonine kinase, and 
localize it at the plasma membrane. This step is essential for Raf activation, 
that is reached by several phosphorylations on Ser-Thr and Tyr residues. 
Successively Raf phosphorylates MAPKK, which phosphorylates in turn ERK 
(Extracellular Signal Regulated Kinase). ERK can phosphorylate many 
transcriptional factors, among this Elk1 that increase the transcription of fos, an 
immediate early gene of the cell cycle. The net result is the induction of 
proliferation or differentiation depends on the activating stimulus and cellular 
system (Fig.1) (Kufe, c2003 ). 
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Figure 1: MAPK cascade. The binding of a growth factor (GF) to the tyorsine kinase 
receptor (RTK) induces the dimerization of the receptor and its autophosphorylation. An 
adaptor protein (Grb2) binds the activated receptor and recruits a nucleotide exchange factor 
(SOS), which binds and activates Ras. Ras activates Raf-1 that starts the phosphorylation 
cascade leading to Erk phosphorylation and activation. 
 
Another pathway activated by Ras is the PI3K (Phosphatidyl-Inositol-3-
Kinase) one, involved in the cell survival and growth control (Shaw and 
Cantley, 2006).  
 
2b. Ras function and its role in cancer 
Ras can induce proliferation or differentiation depending on the cell type 
and above all the stimulus by which it is activated. For example, in mouse 
fibroblast NIH3T3 the activation of Ras, due to the action of the PDGF, 
triggers to cell proliferation, while in rat pheochromocytoma cells PC12 
induces terminal differentiation after exposure of the cells to NGF. Moreover, 
in PC12 Ras can even induce proliferation if activated by EGF, instead of NGF 
(Pollock et al., 1990). Considering the role of Ras in the cell cycle control, it is 
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not surprising that different mutations of these genes are found in human 
cancers. The main hot-spots for activating Ras mutations are in the GTP 
binding domain, these alterations lead to the constitutive activation of Ras 
disabling it from hydrolyzing GTP. The main aminoacid for this function is the 
Gly in position 12, which is frequently substituted with Val or Asp. The nature 
of the mutation correlates even with the aggressivity of the cancer. In fact, Ras-
Val12 is more frequently associated to advanced and metastatic colon-
carcinoma, while Ras-Asp12 is more often present in benign human colorectal 
cancer. On a molecular point of view the difference between these two 
mutations is that Ras-Val12 activates the Erk pathway, on the other end Ras-
Asp12 stimulates the PI3K and FAK pathway (Cespedes et al., 2006). 
 
3. PI3Ks 
PI3Ks are some of the main players in the pathways regulating cell 
proliferation, survival and motility. They phosphorylate the inositol on the 
position 3 and can generate inositol 3 monophosphate, 1,3 diphosphate and 
3,4,5 triphosphate. Depending on the structure and the substrate specificity 
PI3Ks are divided into 3 classes (Fig.2) (Walker et al., 1999). 
Class I PI3Ks preferentially phosphorylates phosphatidilinositol 4,5 
diphosphate (PtdIns(4,5)P2) in vivo, this class can be divided into two 
subclasses: IA and IB. The PI3Ks IA are p110α, β and δ, all of which bind an 
adaptor molecule of 85 KDa (p85) that is required for the binding to the 
tyrosine kinase receptor, by which the enzyme is activated. The class IB is 
activated by heterotrimeric G-proteins subunit and they require the binding to a 
p101 adaptor molecule for their full activation. All the enzyme belonging to 
class I are characterized by an N-terminal Ras Binding Domain (RBD), this 
implies that Ras can activate them. 
Class II enzymes are large proteins (170-210 KDa) characterized by the 
PIK domain, 50% similar to the one of PI3Ks of class I, and a C2 C-term 
domain. Another characteristic domain is the PX, common to molecule such as 
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NADPH-oxidase, phox-40 and phox-47. In vitro class II enzymes 
preferentially phosphorylate PtdIns and PtdIns-4-P. 
The prototype of class III enzymes, VPS34, was first identified in yeast in a 
screening for mutants defective in protein sorting.  This protein is associated 
with a serine-threonine kinase, VPS15, which is essential for the intracellular 
trafficking. VPS15 recruits VPS34 under the cellular membrane and enhances 
VPS34 lipid kinase activity. The preferential substrate of VPS34 is PtdIns. The 
analog in mammalian cell has been identified; it is a heterodimeric protein and 
is associated with a phosphatidylinositol transfer protein, which stimulates its 
activity. This class of PI3Ks lacks the RBD (Fruman et al., 1998; 
Vanhaesebroeck and Waterfield, 1999; Walker et al., 1999). 
 
Figure 2: Classes of PI3Ks. The table illustrates the classes of PI3Ks and the defining 
characteristic of each one. (Vanhaesebroeck B.,and Waterfield M. D., Experimental Cell 
Research,1999; 253, 239–254) 
 
3a. Structure and function of p85PI3K
p85PI3K is the regulatory subunit of PI3K, there are three different isoforms, 
α, β and γ. They share a high homology and their characteristic domains are: a) 
an N-terminal SH3 binding domain; b) a Proline Rich Domain (PRD); c) a 
BCR domain, which is homolog to the GTPase of the Rho family; d) a second 
PRD; e) two SH2 domains separated by a region called iSH2 (inter-SH2 
domain) (Fig.3). 
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Figure 3: Structure of p85αPI3K. P1 and P2 are respectively the Proline Rich Domain 1 
and 2. 
 
It has been shown that the SH3 and the BCR domain are involved in the 
dimerization of p85PI3K, that, in turn, may be involved in the stabilization of 
p110PI3K (Harpur et al., 1999). The interaction between p85PI3K and p110PI3K is 
mediated by iSH2 domain, which binds the N-terminal of p110PI3K. Previous 
studies have shown that p85PI3K can both stabilize p110PI3K increasing its 
activity and inhibit it. The actual model to explain the opposite effects of 
p85PI3K on PI3K activity is that the binding of p110PI3K to p85PI3K is necessary 
to stabilize the protein. The binding to p85PI3K itself is not sufficient to activate 
the lipid kinase activity of p110PI3K, to reach the effect it is necessary a 
conformational change, which is induced by the phosphopeptide binding to the 
SH2 domain. Experiment with deletion mutant showed that the nSH2 is 
necessary and sufficient for the activation of p110PI3K. In contrast, if the 
phosphopetides bind cSH2, to activate p110PI3K, the first 322 aminoacids (SH3 
domain, the first PRD and the BH domain) and the nSH2 are required 
(Carpenter et al., 1993; Klippel et al., 1993; Dhand et al., 1994a; Holt et al., 
1994; Hu and Schlessinger, 1994; Yu et al., 1998). Moreover, both the binding 
of phosphopeptide to the nSH2 and the one to the cSH2 induce a 
conformational change at the nSH2 (Fig. 4). 
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Figure 4: Activation of PI3K. The binding of phosphoprotein at the nSH2 induces a 
conformational change at the same domain activating PI3K (A), the binding at the cSH2 
induces a conformational change at the nSH2 through the N-terminal of p85αPI3K activating the 
enzyme (B). (Yu J. et al, J. Biol. Chem., 1998; 273:30199-30203) 
 
3b. Pathways downstream of PI3K 
The PIs generated by PI3K may act on different molecules involved in 
vesicle trafficking and budding, cell survival and proliferation and protein 
synthesis. 
All PI3K’s downstream effectors are characterized by a Pleckstrin 
Homology (PH) domain, which represents the binding site for the PI. The main 
effector of PI3K is the serine-threonine kinase AKT.  
The binding of the PI to AKT induce a conformational change in the 
molecule that exposes the threonine 308 and the serine 473. These residues are 
substrate for two kinases: PI3K Dependent Kinase (PDK) 1 and 2. AKT, in 
turn, regulate many substrates involved in cell survival, proliferation and 
protein synthesis (Fig.5): 
1) Cell survival. AKT activate IKK, once activated this kinase 
phosphorylates IkB (the inhibitor of NFkB) inducing the realease of 
NFkB from the binding to IkB. AKT can even activate MDM2, 
resulting in the inhibition of p53, and can inhibit the pro-apoptotic 
protein bad. All these mechanisms contribute to induction of cell 
survival (Lodish, c1999 ). 
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2) Cell proliferation. PI3K activity is required at different steps of 
the cell cycle, first at the transition G0-G1, a second peak is at mid G1 and 
it is necessary for the entry in S-phase and induction of DNA synthesis and 
for the G2-M transition. AKT is involved at all the steps. Its main role in 
cell cycle control is the inhibition of Glycogen Synthase Kinase 3β 
(GSK3β) and the transcriptional factors FOXO. GSK is a negative 
regulator of cell cycle since it targets cyclin E, cyclin D and Myc for 
degradation. FOXO is the O subgroup of Forkhead transcriptional factors 
(TFs) family. These TFs induce the expression of molecule essential for 
quiescence maintenance, such as p27KIP , p130 and cyclin G2 (Martinez-
Gac et al., 2004; Garcia et al., 2006).  
3) Protein Synthesis. AKT activates  mTOR and p70S6K inducing 
protein synthesis, and, in turn, increase of cell mass (cell growth) that is 
essential for cell division (Garcia et al., 2006).  
 
        
 
Figure 5: PI3K-AKT pathway. The activation of PI3K leads to the formation of 
PtdIns(3,4,5)P3 (PIP3) that activates directly or indirectly AKT. AKT phosphorylates different 
substrates controlling cell proliferation, survival and growth (protein synthesis). 
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3c. PI3K function and its role in cancer 
Class IA PI3Ks play a main role in control cell replication, migration, 
survival and glucose homeostasis (Kufe, c2003 ). The oncogenic potential of 
PI3K and its target AKT was first revealed by two retroviruses (Bader et al., 
2005; Kang et al., 2005):  
1) the avian sarcoma virus ASV16, which encodes a constitutive 
active  homolog of p110αPI3K, P3k, that is fused to the Gag sequence of 
the virus;  
2) the murine lymphoma virus AKT8, that encodes for 
constitutively active AKT. 
The oncogenicity of the two viral proteins is due to the constitutive 
membrane addresses, because of the myristoylation, and their constitutive 
kinase activity. In fact, if the wild type p110αPI3K is overexpressed in normal 
chicken embryo fibroblast no alteration of cell growth is observed. In contrast, 
mutant p110αPI3K can induce strong oncogenic transformation in the same 
cellular system.  
In the few past years, different mutations of PIK3CA, the gene encoding 
p110αPI3K, have been identified, outlining the role of PI3K in human cancer. 
These mutations are somatic missense ones, they are tumor-specific and they 
map to a few hot-spots. The three most common mutations are E542K, E545K 
and H1014R. The H1014R mutation is in the substrate binding pocket and this 
suggest an increased binding affinity of mutant PI3K for PtdIns(4,5)P2. The 
other two mutation, instead, are in the helical domain. It is not likely that they 
increase the catalytic activity of the enzyme since they are too far from the 
catalytic domain. Considering that both p85PI3K and Ras bind to the N-terminal 
of p110PI3K (even if not to the helical domain), it is possible that the E542K and 
the E545K substitution alter the binding to these proteins, or to other unknown 
regulatory proteins.  
Other mutations that constitutively activate PI3K are the p85PI3K mutations. 
p65αPI3K is the first oncogenic variant of p85PI3K that has been identified. 
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Jiemenez et al.in 1998 (Jimenez et al., 1998), in fact, cloned p65αPI3K from a 
murine lymphoma generated through X-Ray irradiation. This variant lacks part 
of the iSH2 and the cSH2, can still bind p110αPI3K and can localize the PI3K 
complex at the plasmamembrane. This results in the constitutive activity of the 
enzyme and contributes to cellular transformation. Another oncogenic variant 
of  p85αPI3K is p76αPI3K, this lacks the cSH2 and it has been found in a 
Hodgkin’s lymphoma cell line (Jucker et al., 2002). In human ovarian and 
colon cancer Philip et al. found a few mutation in splicing site leading to exon 
13 skipping, so to the deletion of the region of the iSH2 proximal to serine608 
(Philp et al., 2001). The serine608 is an important auotregulatory site. Its 
phosphorylation by p110αPI3K results in a three-sevenfold decrease of the lipid 
kinase activity (Carpenter et al., 1993; Dhand et al., 1994b). Even the 
oncogenic variants previously described impair the ser608 phosphorylation. 
Other mutations frequently found in human cancer are: 
1) mutation of the upstream receptor, such as PDGF, EGF, ErbB2. 
The increased expression and activation of the receptors result in 
increased activity of the downstream effectors (Osaki et al., 2004);  
2) mutation of phosphatase PTEN (phosphatase and tensin 
homologue deleted on chromosome 10). PTEN dephosphorylates PIP3 
to generate PIP2 downregulating the PI3K pathway. It is a tumor 
suppressor gene frequently inactivated in primary cancers in thyroid, 
breast, prostate, uterus, central nervous system, soft tissue and above all 
colorectal cancer (Osaki et al., 2004).  
3) mutation of AKT, amplification of AKT2 are present in ≈15% of 
human ovarian cancer and ≈10% of human pancreatic cancer. Its 
amplification is not due to polysomy of the chomosome 19, where AKT 
gene is located (Cheng et al., 1996). Moreover, AKT alteration in 
cancer correlates with a poor prognosis because of the increased cell 
motility,that results in an higher tumor invasiveness (Balsara et al., 
2004). In recent studies it has been shown a strong prognostic 
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significance for AKT constitutive activation in acute myeloid leukemia, 
it correlates, in fact, with a shorter overall survival (Min et al., 2003).  
 
4. Crosstalk between different signaling pathways: the paradox of 
cAMP  
The different signaling pathways in the cell form complicate networks, 
where the many transduction systems communicate with each other in feed-
forward and feed-back regulatory loops. Considering that it exists a wide range 
of specialized cell types, it is essential for the ubiqitously expressed signal 
transduction systems to be adapted to meet the specific requirements of the 
cell. It is paradigmatic, in this context, the role of cAMP. In fact, in cell such as 
rat thyroid cell FRTL-5 and Swiss 3T3 fibroblast cAMP induces proliferation 
(Lee et al., 1998; Ariga et al., 2000), while in most cell types (Magnaldo et al., 
1989) it inhibits proliferation. How is it possible is not yet fully understood. It 
has been proposed that cAMP inhibits proliferation through the inhibition of 
ERK. This is due to mechanisms PKA-dependent and others cAMP, but not 
PKA, dependent. First, PKA can phosphorylate Raf-1 on serine 43, 259 and 
621 blocking Raf-1 activation (Cook et al., 1993; Mischak et al., 1996; Dhillon 
et al., 2002). Second, cAMP activates some cAMP dependent nucleotide 
exchange factor (EPAC) leading to the activation of Rap1. Rap1 is a small G-
protein highly homologue to Ras and binds Raf-1 inhibiting it (Stork and 
Schmitt, 2002). This leads to the cAMP mediated inhibition of proliferation in 
cell as NIH3T3. In cell where proliferation is activated by cAMP, it has been 
proposed that ERK is activated by cAMP in a PKA- independent manner. In 
fact, it has been shown that Rap1 can stimulate the ERK pathway through B-
Raf (Zwartkruis et al., 1998). These observations suggest that the effect of 
cAMP on cell proliferation may depend on the differential expression of Raf 
isoforms in the distinct cell types (Fig.6).  
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Figure 6: cAMP through Rap1 regulates ERK activity. cAMP activates Rap1, in B-Raf 
negative cells this leads to Raf-1 inhibition and suppresses ERK activity (A), instead, in B-Raf 
positive cells (B), Rap1 activates ERK.(Stork and Schmitt, TRENDS  in Cell Biology, 2002; 
258-266) 
 
Another example of crosstalk between two pathways is the Raf-AKT one. 
RTKs activate both the PI3K and Ras pathways. In MCF-7 cells, a human 
breast cancer cell line, Insulin-like Growth Factor I (IGF-I) induces cell 
proliferation and survival through PI3K-AKT and growth arrest and 
differentiation through Ras-Raf. According to Moelling et al (2002), the effect 
of IGF-I on MCF-7 cells depends on the concentration of the growth factor. In 
particular, high doses of IGF-I activate AKT quickly and strongly enough to 
suppress Raf-1 activity. AKT, in fact, can phosphorylate Raf-1 on serine 259 
inhibiting it. In this context proliferation is stimulated. Low doses of IGF, 
instead, are not enough to suppress Raf-1, so both pathways are active and the 
differentiation signals are favored over the mitogenic ones (Fig.7, (Moelling et 
al., 2002). 
 
                                                                                               25
 
 
   
Figure 7: AKT-Raf crosstalk in MCF-7 cells. High concentration of IGF-I leads to the 
AKT dependent phosphorylation of Raf-1 and induction of the proliferation. This effect is 
reverted by LY294002, a specific PI3K inhibitor. Low dose of IGF-I activate both PI3K and 
Raf-1 (Moelling et al, J. Biol. Chem, 2002; 31099-31106). 
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Aims of the study 
 
It has been previously shown in our laboratory that PI3K interacts with 
Ras upon cAMP stimulation, and this complex is essential for G1-S transition 
in these cells. 
Moreover, the formation of the complex was H89 sensitive, indicating 
that PKA was involed in the regulation of the interaction. In vitro kinase assay 
revealed that p85αPI3K was efficiently phosphorylated. These data suggested 
that cAMP-PKA selectively influences Ras effector pathway through p85αPI3K 
phosphorylation.  
1) The first part of the work presented here, focuses on the 
identification and validation of the PKA phosphorylation site on p85αPI3K.  
2) The second part, instead, investigates the biological role of this 
phosphorylation in different cell types. It is worth noting that cAMP leads to 
opposite effects on proliferation depending on the cellular system (Pastan et 
al., 1975). To investigate the role of phosphorylation of p85αPI3K and its 
association with Ras in the regulation of cell proliferation, the experiments 
presented were performed both in cells where proliferation was inhibited 
(fibroblasts NIH 3T3) or stimulated (TSH-dependent cells) by cAMP.  
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Materials and Methods 
 
1. Plasmid construction 
The cDNA encoding for bovine p85αPI3K wild type (acc. n.:163476) was 
cloned in the pSG5 vector (gift of Dr. J. Downward). The region of p85αPI3K 
from the Xho I restriction site in position 1014 (acc. n.:163476) was amplified 
by PCR with a 3’end primer containing the Flag sequence (MDYKDDDDK) 
and a BamHI restriction site. 
The PCR product was sub-cloned in the II-TOPO vector (Invitrogen), 
digested with Xho I and BamHI, extracted and ligated to a pSG5-p85αPI3K 
vector previously digested with the same restriction enzymes. The vector 
encoding p85αPI3K-flag was then used as template for site-directed mutagenesis 
(QuickChange Site-Directed Mutagenesis Kit, Stratagene) to convert serine 83 
in alanine or aspartic acid. All the constructs were verified by DNA sequence 
analysis. 
 
2. Materials and Reagents 
Unless otherwise specified, drugs and chemicals were obtained from Sigma 
Aldrich and cell culture supplies were purchased from standard suppliers, e.g. 
Falcon, Life Technologies inc., Hyclone. 
The antibodies used were: anti-pan-Ras (clone 10, mouse monoclonal, 
UBI), anti-Raf1 (rabbit polyclonal, Santa Cruz), anti-p85PI3K (rabbit polyclonal, 
UBI), anti-P-Serine (rabbit polyclonal, Zymed), anti-Erk 1/2 (rabbit polyclonal, 
Santa Cruz), anti-P-Erk 1/2 (mouse monoclonal, Santa Cruz), anti-P-Akt ser 
473 (rabbit polyclonal, Cell Signaling), anti-Akt (rabbit polyclonal, Cell 
Signaling), anti P-Gsk ser 21/9(rabbit polyclonal, Cell signaling), ant GSKα/β 
(mouse monoclonal, UBI). The anti-flag antibody was the mouse monoclonal 
Sigma M2 antibody.  
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3. Cell culture and transfections 
Cell lines used in the experiments were grown as follows: 
1. murine fibroblasts NIH 3T3 in DMEM 10% bovine serum; 
2. rat thyroid cells FRTL-5 in medium with 5% calf serum and six 
hormones (1mU/ml TSH, 1µg/ml Insulin, 3.6 µg/ml 
Hydrocortisone, 5 µg/ml Transferrin, 10 ng/ml Somatostatin, 20 
µg/ml Glycil-histidil-lysine); 
3. NTCRII cells in DMEM 10% foetal bovine serum. Considering 
that these cells were conditional stable clones of RIIβ and TSHR, 
the medium was supplemented with puromycin 2.5 µg/ml and 
geneticin (G418) 200 µg/ml to maintain the selection and 
tetracycline 1.0 µg/ml to keep the genes silenced. The selection and 
tetracycline were removed 48 hr before starting the experimental 
procedures described in the results (Porcellini et al., 2003); 
4. MCF-7 breast cancer cells in  DMEM with 5% foetal bovine 
serum, supplemented with 6 ng/ml insulin and 3,75 ng/ml 
hydrocortisone; 
5. HeLa cells in RPMI 10% foetal bovine serum. 
All the media were supplemented with penicillin/streptomycin 
100mU/mL and 2 mM glutamine. 
Cells were transfected with lipofectamine according to the 
manufacturer’s recommendations (Gibco Invitrogen). Briefly cells were 
transfected at 80% confluence with 4µg of DNA for each 100mm dish. The 
lipofectamine was used 1µL for each µg of DNA. The mix DNA-
lipofectamine was incubated 45 minutes at room temperature to allow the 
formation of the precipitates. Before adding the mixture cells were washed 
with PBS and the growing medium was replaced with medium without 
serum and antibiotics. 5 hours after the adding of the mixture the normal 
concentration of serum was restored.  
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4. Cell lysis and immunoprecipitation  
Cells were collected in ice-cold PBS and spun at 1500 rpm for 3 minutes. 
Pellets were re-suspended in lysis buffer (50 mM Tris-HCl pH 7.4, 1% Nonidet 
NP-40, 100 mM NaCl, 2 mM EDTA 50 mM NaF, 0.1 mM NaVO3 1 mM β-
glycerophosphate, 2.5 mM sodium pyrophosphate and a protease inhibitor 
cocktail). After 15 minutes incubation on ice the samples were spun at 13000 
rpm for 10 minutes. Cell lysates were transferred to other tubes and quantified 
at the spectrophotometer using the Bradford assay (BioRad protein assay). 
Protein lysates were diluted to 2 mg/ml and were incubated with 4 µg of 
antibody/0.5-1 mg of protein at 4°C in gentle rock agitation overnight. At the 
end of incubation, 20 µl of A/G plus were added to samples and the 
immunoprecipitates were washed three times with lysis buffer and then 
collected by centrifugation. The bound proteins were eluted with one volume 
of 2× Laemmli buffer or, when indicated, using 0.1 M glycine HCl pH 3.5. In 
the latter case, 1M Tris-HCl pH 8 was added to the eluted proteins to neutralize 
the pH. 
 
5. GST pull-down 
GST pull-down were performed as described by (Grieco et al., 1996). 
Briefly, cells were lysed in 200mM NaCl, 50mM Tris-Hcl pH 7.5, 2mM 
MgCl2, 10% glycerol, 1% NP 40, 10µg/ml Trypsin inhibitor, 1µg/ml aprotinin, 
1µg/ml leupeptin, 10mM NaF, 10mM Na3VO4 (Pull Down buffer). 1 mg of 
protein extract was incubated with 1 microgram of GST-RIIβ fusion protein or 
the control protein (GST) for 4 hours at 4°C in gentle rock agitation. The 
pellets were washed 5 times in pull down buffer and re-suspended in one 
volume of 2× Laemmli buffer. 
 
6. Western blot 
Total cell extracts and immunoprecipitates were separated on 10% SDS-
PAGE and transferred onto nitrocellulose filter. The filters were blocked in 
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TBS 0,1% TWEEN (TBS-T) 5% not-fat-dry-milk (NFM) for 1 hour at room 
temperature. The filters were washed three times with TBS-T and incubated 
with the indicated primary antibody. Primary antibodies were diluted according 
to the manufacturer’s recommendations. The filters were successively washed 
three times with TBS-T and incubated with the peroxidase conjugated antibody 
diluted 1:3000 in TBS-T 3% NFM. The signal was detected with 
chemiluminescence system (Feliciello et al., 2000). 
 
7. In vitro phosphorylation 
HeLa cells were transiently transfected with p85αPI3K-flag and p85A. 48 
hours after transfection, cell lysates were immunoprecipitated with non-
immune IgG or anti-flag antibody 15 h at 4°C. Protein A/G bound 
immunoprecipitates were washed twice with lysis buffer and finally with 
Kinase buffer (Hepes 20 mM, MgCl2 10 mM, pH 7.4). The washed 
immunoprecipitates were treated with 0.4 µg of Protein Kinase A. Each aliquot 
was incubated in a final volume of 30 µl of Kinase buffer containing 10-5 M 
cAMP, 100 µM ATP and 10 µCi[γ32P-ATP] for 30 minutes at 30°C. The 
reaction was stopped by adding one volume of 2× Laemmli buffer (Ciullo et 
al., 2001). 
 
8. In vitro protein synthesis  
p110αPI3K and p85αPI3K wild type or p85A  or p85D were co-transcribed 
and co-translated in vitro in [35S]methionine-containing reticulocyte lysate 
according to the manufacturer’s recommendations. The conditions of the 
reaction were optimized to reach the same efficiency of synthesis of the co-
transcripted and co-translated proteins. The amount of template used was 1µg, 
and the optimal ratios of the two template were: p85αPI3K wt / p110αPI3K 1:2; 
p85A/ p110αPI3K and p85D/ p110αPI3K 2:1. The reactions were incubated for 
1h 30’ at 30°C and diluted 1:100 with PBS conatining 0.5% Triton X-100 and 
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protein inhibitors. The control reaction was performed using only p110αPI3K as 
template. 
The diluted lysates were immunoprecipitated with the anti-Flag antibody, 
as described previously. The immunocomplexes were washed three times with 
PBS-0.5% Triton X-100, solubilized in 2× Laemmli buffer  and boiled. The 
samples were separated on SDS-PAGE. The gel was fixed 30 minutes in a 
solution containing 10% acetic acid and 20% methanol, washed three times in 
deionized water and treated with 100 mM salycilate to enhance the radioactive 
signal. The gel was then dried and expose on a autoradiography film. On the 
gel the input (1 µl of the reaction mix using 1 µg of plasmid as template) was 
loaded as control of the reaction.  
 
  9. Apoptosis assays  
NIH 3T3 were co-transfected with GFP and the indicated vector. 48 hours 
later cells were plated in DMEM 0,1% bovine serum -/+ 200µM CPT-cAMP 
on plates covered with 2% agarose (anoikis) . After a 5 hours incubation cells 
were collected and washed three times with PBS before the 5 minutes 
incubation with propidium iodide. Successively cells were analyzed by 
Fluorescent Activated Cell Sorter (FACS) using CELLQuest software (Becton 
Dickinson). The percentage of death (PI positive cells, i.e. red population) was 
calculated on the population positive for GFP (green population). The 
experiments were performed in triplicate. 
5*105 NTCRII cells were transfected as described. 24 hours later cells the 
normal medium was replaced by 0,5% serum medium with or without 
10mU/mL TSH or 100µM cAMP. 18 hr after treatment, cells were fixed in 2% 
paraformaldehyde/1X PBS, 10 min, RT and washed one time in PBS + 50 mM 
glycine for 10 min at RT and 3 times for 5 min in PBS. Cells were 
permeabilized with 0.5% triton X-100/ 1X PBS for 10 min, washed 3 x 5 min 
in PBS and incubated with 100 µl of 1X TdT reaction mix. TUNEL reaction 
was carried out at 37°C for 60 min using 15 Units of TdT (ROCHE) and 2 µl 
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of 2mM BrdUTP. BrdUTP incorporation was revealed by anti-BrdU-FITC and 
the samples were then stained in Propidium Iodide. The data were acquired and 
analyzed by CELLQuest software for bivariate-analysis of DNA content versus 
BrdU. Experiments were performed in triplicate. 
 
10. Cell growth analysis 
5*105 cells were transfected with the indicated vectors. 48 hours later cells  
were plated in 60 mm dishes and growth in 0,5% serum containing medium. 
After 18 hr cells were induced into the cycle with 10 mU/ml TSH or EGF 100 
ng/ml. Cells were collected and washed twice with PBS. Successively cells 
were  fixed in 70% ethanol and stained for 30 min at room temperature in 0.1% 
triton-X100, 0.2 mg/ml DNase-free RnaseA, 20 µg/ml Propidium Iodide. 
Cells were acquired using the FACScan Flow Cytometer (Becton 
Dickinson) and analyzed by Cell Fit Cell-Cycle Analysis Version 2 to define 
the percentage of cells in the different phases of cell cycle. 
 
11. 5’-bromo-2’-deoxyuridine (BrdU) labelling 
BrdU incorporation was assayed in a pulse-chase experiment. Cells were 
labelled for 30 min with BrdU to a final concentration of 20 µg/ml and 
harvested at 0, 90 and 270 min. After treatment, cells were fixed in ice-cold 
70% ethanol for 4 hr at +4 °C and washed 3 times for in PBS. Cell pellet was 
re-suspended in 0.25 ml of 1N HCL and let stand 20 min at room temperature. 
After acidic denaturation of DNA, cells were washed 2 times in 
phosphate/citric buffer (0.2 M Na2HPO4; pH 7.4). BrdU incorporation was 
revealed by anti-BrdU-FITC and then stained for 30 min at room temperature 
in 0.1% triton-X100, 0.2 mg/ml DNase-free RnaseA, 20 µg/ml Propidium 
Iodide. Fluorescence was determined by using the FACScan Flow Cytometer. 
Experiments were performed in triplicate. The data were acquired and analyzed 
by CELLQuest software for bivariate-analysis of DNA content versus BrdU 
and by Cell Fit Cell-Cycle Analysis Version 2 for DNA content analysis. 
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12. Lipid kinase assay 
Lipid kinase activity was determined as described by (Maier et al., 1999). 
Briefly, the assays were carried out in a final volume of 50 µl containing 0.1% 
bovine serum albumin, 1 mM EGTA, 120 mM NaCl, 40 mM HEPES, pH 7.4, 
1 mM dithiothreitol, 1 mM -glycerophosphate, 7mM MgCl2 (buffer E). Lipid 
vesicles (30 µl containing 320 µM phosphatidylethanolamine, 300 µM 
phosphatidylserine, 140 µM phosphatidylcholine, 30 µM sphingomyelin, 
supplemented with 40 µM PI-4,5-P2 in buffer E) were sonicated 1 hour and 
incubated on ice 10 min. The immunoprecipitates were added to the lipid 
mixture and incubated for 10 min at 4°C in a final volume of 40 µl. The 
reaction was started by adding 40 µM ATP (1 µCi of [-32P]ATP in 10 µl of the 
assay buffer. The reaction was incubated 15 minutes at 30°C and then stopped 
with 150 µl of 1 N ice-cold HCl. The lipids were extracted by vortexing 
samples with 500 µl of chloroform/methanol (1:1). After centrifugation the 
organic phase was washed twice with 200 µl of 1 N HCl. Phosphorylated lipids 
were separated by TLC developed in CHCl3/CH3OH/H2O/NH4OH 
(60:47:11.3:2), dried, and visualized by autoradiography and quantified with 
Phosphor-Imager. 
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RESULTS 
 
1. PKA phosphorylates serine 83 of p85αPI3K 
It has been previously shown in our laboratory that PKA efficiently 
phosphorylates p85αPI3K in vitro (Ciullo et al., 2001). The sequence analysis 
revealed a PKA consensus in the sequence of bovine p85αPI3K (KKIS).  This 
consensus is highly conserved in evolution (Fig.8): KKIS in bovine/human and 
KRIS in mouse/rat. Moreover, no PKA consensus was found in p85βPI3K. 
 
 
Figure 8: Alignment of p85αPI3K sequences from different species. p85αPI3K presents an 
highly conserved PKA consensus at the residues 80-83. 
 
To determine if this is a bona fide PKA phosphorylation site and its 
biologiacal role, the serine in the consensus (serine 83) was substituted with 
alanine to prevent the phosphorylation or aspartate to mimic it. To distinguish 
the exogenous from the endogenous protein, wild-type p85αPI3K encoding 
cDNA was fused to a C-terminal Flag sequence (MDYKDDDDK ) and 
subcloned in a pSG5 vector. The tagged wild-type cDNA was used as a 
template for the mutagenesis reaction (see Materials and Methods). 
 
1a. In vitro phosphorylation 
The wild-type and the alanine tagged proteins were transiently expressed in 
Hela cells. The cell lysates were immunoprecipitated with anti-Flag antibody 
or non-immune IgG (SNI) as described in Materials and Methods. The 
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immunoprecipitates were incubated in vitro in kinase buffer containing 10-5 M 
cAMP, 100 µM ATP and 10 µCi[γ32P-ATP] for 30 minutes at 30°C, with or 
without recombinant PKA (cPKA). The immunoprecipitates were separated on 
SDS-PAGE and analysed by western blot with anti-p85 antibody (Fig. 9, upper 
panel) and by autoradiography (Fig.9, bottom panel). 
 
 Figure 9: In vitro phosphorylation of serine 83 in p85αPI3K by cAMP-PKA. HeLa cells 
were transiently transfected with p85αPI3K-flag wild type or p85A; 48 hours after transfection, 
cell lysates were immunoprecipitated and in vitro phosphorylated with cPKA as described in 
Material and Methods. Sample aliquots were run on SDS-PAGE and subjected to immunoblot 
(upper panel) or autoradiography (bottom panel). 
 
p85αPI3K wild-type, but not p85A, was efficiently phosphorylated in vitro 
by PKA. This reaction was dependent on cPKA, because omission of cPKA 
from the mixture did not results in p85αPI3K phosphorylation. The western blot 
in the upper panel shows that the immunoprecipitation efficiency was 
comparable in all the samples. 
This result indicates that serine 83 is the PKA phosphorylation site on 
p85αPI3K. 
 
1b.In vivo phosphorylation 
To verify that PKA phosphorylates p85αPI3K not only in vitro but also in 
vivo quiescent breast carcinoma cells (MCF7), were transiently transfected 
with p85WT or p85A encoding vector. 24 hours after transfection cells were 
stimulated with 100µM CPT-cAMP or left untreated. Protein lysates were 
immunoprecipitated with anti-Flag antibody and the immunoprecipitates were 
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separated on SDS-PAGE. The proteins were transferred onto nitrocellulose 
filter and analyzed by western blot with anti-p85 and anti-phospho-serine (anti-
P-ser) antibodies. Figure 10A shows that p85WT, but not p85A, was efficiently 
phosphorylated following cAMP treatment (bottom panel). The amount of 
protein in all samples was the same (upper panel).  
 
igure 10: In vivo phosphorylation of serine 83 in p85α  by cAMP-PKA.  (A). 
Quiescen αPI3K ion 
cell  
d 
 
o monitor the phosphorylation of the endogenous protein, un-transfected 
mu
t PKA phosphorylates p85αPI3K on 
ser
F PI3K
t MCF7cells were transfected with p85  or p85A. 24 hours after the transfect
s were treated with 100 µM cAMP. The anti-Flag immunoprecipitate were analyzed by
western blot with anti-p85PI3K (upper panel) and anti-phosphoserine (lower panel) antibodies. 
(B) NIH 3T3 were serum starved in DMEM 0,1% calf serum, after 16 hours they were treate
with or without 100 µM cAMP for 10’ after a 30’ minutes pretreatment with or without 10 µM
H89. Cell lysates were immunoprecipatated with anti-p85 antibody and analysed by western 
blot with anti-p85 antibody (upper panel) and anti-phosphoserine (lower panel). 
 
T
rine fibroblasts NIH 3T3 were serum starved for 16 hours and treated with 
or without cAMP, after a pre-treatment with or without 10µM H89, a PKA 
inhibitor. Cell lysates were immunoprecipitated with anti-p85 antibody and 
analyzed with anti-p85 and anti-P-ser antibodies. cAMP induced p85αPI3K 
phosphorylation (Fig 10B, bottom panel). This event was PKA dependent, 
since H89 abolished the phosphorylation. The amount of protein was the same 
in all the samples (Fig 10B, upper panel). 
Taken together these data indicate tha
ine 83, and this site is the major, if not the only, PKA phosphorylation site 
on the protein, since p85A was not phosphorylated neither in vitro nor in vivo. 
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2. Biological effects following the phosphorylation of p85αPI3K in NIH 
3T
oth cAMP and PI3K regulate cell survival and growth (see Background). 
In 
-AKT is 
one
a. cAMP induced-survival depends on phosphorylation of p85αPI3K
 is 
an 
 83 on the anoikis, NIH 3T3 cells 
we
3 
B
particular cAMP protects cells from serum deprivation induced apoptosis 
(Affaitati et al., 2003) and regulates cell proliferation in different manner 
depending on cell type (Pastan et al., 1975).In fact, cAMP induces proliferation 
in such cells as thyroid cell FRTL5 (Lee et al., 1998; Ariga et al., 2000), while 
it inhibits proliferation in most cell types, such as NIH 3T3 (Magnaldo et al., 
1989). The mechanisms underlying these effects are not yet defined.  
On the other side, as discussed in the Background Section, PI3K
 of the most important pathway promoting survival and cell growth. These 
observations suggest that cAMP-PKA dependent phosphorylation of serine 83 
may affect these important biological functions. 
 
2
To validate our hypothesis, inhibition of anoikis has been tested. Anoikis
apoptotic pathway triggered by loss of cell adhesion to the extracellular 
matrix and strictly dependent on PI3K (Frisch and Francis, 1994; Khwaja et 
al., 1997). In cell culture it can be easily assayed by culturing the cells on 
plates covered with a thin 2% agarose layer.  
To test the effects of mutagenesis of serine
re co-transfected with a GFP encoding vector and the wild type or mutant 
vesions of p85αPI3K. 48h later, the cells were plated in 0,1% CS -/+ 200 µM 
CPT-cAMP  medium on 2% agarose. After 5h cells were stained with 
propidium iodide and the percentage of apoptosis determined by FACS 
analysis. The histogram in figure 11B shows that cAMP protected cells from 
apoptosis, and the over-expression of p85WT amplified the effect of cAMP. 
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Figure 11: Analysis of cell survival. NIH 3T3 were co-transfected with a GFP encoding 
vector and the wild type and mutant of p85αPI3K. (A) The expression was analyzed by western 
blot. the exogenous molecule is the upper band of the doublet. (B) fraction of apoptotic cells 
after anoikis was determined by FACS analysis . The data are the mean of three independent 
experiments;  * indicates p ≤  0.01 comparing cell death in the presence of cAMP in all 
samples.  
 
The expression of p85A abolished the cAMP mediated protection (*). On 
the other side, the p85D expressing cells are more resistant to anoikis in 
absence of cAMP (**). This indicates that, at least in part, the S83D 
substitution can mimic cAMP effects on survival. It is worth noting that p85D 
expressing cells showed a reduced response to cAMP, probably caused by low 
expression of p85D (fig 11A).  
These data indicate that p85αPI3K mediates the cytoprotective effect of 
cAMP during anoikis and its phosphorylation is necessary for the cAMP 
induced survival. 
 
2b. cAMP mediated G1-S arrest requires phosphorylation of p85αPI3K
To test if the phosphorylation of p85αPI3K is involved in cAMP growth 
arrest,  the wild type and the mutant p85αPI3K were expressed in NIH 3T3. 
Cells were serum-starved 15 hours and induced into the cycle with 2 % serum 
in the presence or absence of cAMP  200 µM. 12 hours later cells were 
collected in ice cold PBS, fixed with 70% ice cold ethanol and stained with 
propidium iodide and then FACS analyzed. Fig.12A and 12B show that cAMP 
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accumulated cells in G1 and reduced the number of cells in S-phase. The 
expression of both mutants abolished the response to cAMP. p85A was not 
sensitive to cAMP arrest while the p85D expressing cells accumulated in G1 
even in the absence of cAMP.  
 
Figure 12: Analysis of cell proliferation. Transfected NIH 3T3 were serum starved in the 
presence or absence of 200µM cAMP for 12h and then analyzed by FACS to determine the 
percentage of cells in G1 (A) and  S-phase (B) The data are the mean of three independent 
experiments. * indicates p ≤  0.01 basal versus cAMP; ** p ≤  0.01 basal p85A versus p85D; 
*** p ≤  0.01  basal   p85α wild type, A or D-transfected cells versus control plasmid-
expressing cells. (C) Pulse (30’)-chase of BrdU incorporation. The columns represent the 
fraction of labeled cells stained with propidium iodide at 0 (black columns), 90 (gray columns) 
and 270 minutes (white columns) from the initial cell cycle induction (10% serum). The data 
are the mean of three independent experiments. 
 
In order to test if these effect were caused by difference in the number of 
cells entering the S-phase, instead of the alteration of the S-phase progression, 
a BrdU pulse-chase experiment was performed (Fig.12C). The progression in 
S-phase was normal in all cell lines. At 90 minutes p85A expressing cells 
exhibited a higher percentage of BrdU positive cells.  This was caused by an 
overall higher number of p85A expressing cells entering the S-phase compared 
to the controls. 
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These data indicate that PKA-dependent phosphorylation of p85αPI3K 
mediates selectively G1 arrest induced by cAMP, since S phase progression 
was not influenced in cells expressing the mutant versions.  
 
3. Molecular mechanisms regulated by phosphorylation of serine 83 of 
p85αPI3K
It has been previously shown that cAMP-PKA stimulated the interaction 
between PI3K and Ras and this event was necessary for cell cycle progression 
in cells FRTL-5 (Ciullo et al., 2001). Moreover, Ras and PI3K are among the 
major effectors in transduction pathway modulating cell cycle and survival. It 
is possible that cAMP promotes cell survival and induces G1 arrest in NIH 
3T3 stabilizing PI3K/Ras complex through serine 83 phosphorylation and, in 
turn, activating PI3K-AKT pathway. 
 
3a. The phosphorylation of p85αPI3K increases the formation of the 
complex Ras-PI3K 
In order to test our hypothesis, NIH 3T3 were transfected with p85WT or 
mutant encoding vectors. 36 hours later the cells were serum starved and, 
after 16 hours, were treated 10 minutes with or without 200µM cAMP. Cell 
lysates were immunoprecipitated with anti-Flag antibody. The immuno-
precipitates were separated on SDS-PAGE and analyzed by western blot with 
anti-Flag and anti-Ras antibodies. Figure 13A, bottom panel, shows that Ras 
co-immunoprecipitated with p85WT after cAMP treatment, the substitution of 
serine 83 with aspartic acid amplified this effect. On the contrary, Ras was not 
present in p85A immunoprecipitates.  Ras was barely detected in all the 
untreated samples, while the amount of p85αPI3K was the same in all samples 
(upper panel). 
The histogram in Figure 13B is the p85/Ras ratio determined as an 
average of 3 independent experiments.  
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Figure 13: Effects of the substitution of serine 83 on the association Ras-PI3K. NIH 
3T3 were transfected with p85 WT, A or D and straved for 16h. Later on , cells were treated 10 
min with 200 µM CPT-cAMP. The total lysates were immunoprecipitated with anti-Flag 
antibody and analyzed by western blot with anti-p85PI3K and anti-Ras antibody (A). The 
histogram (B) represents the mean of the densitometric analysis of 3 independent experiments.  
 
These data indicate that serine 83 phosphorylation was necessary to 
induce PI3K/Ras interaction, since p85A lost is ability to bind Ras, although it 
was not sufficient, because p85D/Ras association was still dependent on 
cAMP. 
 
3b. The disruption of the phosphorylation site on p85αPI3K did not 
abolish the binding p85αPI3K- p110αPI3K 
Considering that p110αPI3K, and not p85αPI3K, mediates PI3K/Ras 
interaction (Rodriguez-Viciana et al., 1996) it is possible that serine 83 
substitution with alanine may alter the folding of p85αPI3K disrupting the 
p85αPI3K- p110αPI3K binding. 
Since the commercial antibodies versus p110αPI3K are not satisfactory in 
terms of specificity in immunoblot analysis, we decided to study the 
association between p85αPI3K and p110αPI3K using the recombinant proteins. 
To this end we transcribed and translated the vector encoding p85αPI3K and 
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p110αPI3K in reticulocyte lysates, adding 35S-methionine to the reaction to 
label the products. Preliminary experiments indicated that the binding of the 
two proteins was not efficient when the in vitro translation was carried out 
separately.  
To solve this problem, p85αPI3K and p110αPI3K proteins were co-
translated. Successively, the samples were immunoprecipitated with the anti-
Flag antibody, separated on SDS-PAGE and analized by autoradiography. 
Figure 14 shows that 1. The 2 proteins interacted very efficiently in vitro; 2. 
The complex p85αPI3K -p110αPI3K was specific since immunoprecipitation of 
the in vitro translated p110αPI3K with the anti-Flag antibody was negative; 3. 
p85A interacted with p110αPI3K as well as p85αPI3K wild type, p85D instead 
appeared more efficient than the wild type in the formation of the complex 
with p110αPI3K. 
 These results indicate that the S83A substitution did not alter the folding 
of p85αPI3K, and suggest that the phosphorylation of serine 83 of p85αPI3K 
stabilizes the complex PI3K/Ras. This in turn stimulates the association 
p85αPI3K/ p110αPI3K. 
 
Figure 14: Effect of the substituion of serine 83 of p85αPI3K on the association with 
p110αPI3K. [35S]methionine labeled p85αPI3K p110αPI3K where in vitro co-transcripted and co-
translated. The samples where immunoprecipitated with the anti-Flag antibody and analyzed 
by autoradiography (A). The histogram (B) represents the mean of the quantitative analysis of 
3 independent experiments.   
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3c. cAMP-PKA activates PI3K in vitro 
To determine if the phosphorylation of serine 83 influenced PI3K lipid 
kinase activity, NIH 3T3 were transfected with the p85WT encoding vector. 
Cells were serum starved for 16 hours before a 10 minutes treatment with 
200µM cAMP in the presence or absence of H89. Cell lysates were 
immunoprecipitated with anti-Flag antibody, and the immunoprecipitates 
divided into two aliquots. One aliquot was used to test the in vitro lipid kinase 
assay (see Material and Methods). Following a 15 minutes incubation the 
reaction was stopped with 1N HCl and separated by TLC. Considering that 
the lipid substrate added to the mixture was the PI 4,5 diphostate the only 
phosphorylated product detected was the PI 3,4,5 triphosphate (PIP3). The 
other aliquots were used to normalize for total p85αPI3K present in the 
immunoprecipitates, by western blot with anti-p85 antibody. 
Figure 15A shows that cAMP activated PI3K in a PKA dependent 
manner, since this effect was reversed by H89 (upper panel and histogram). 
The amount of p85WT immunoprecipitated was comparable in all the 
samples (bottom panel). 
To verify if cAMP activated PI3K through serine 83 phopshorylation, NIH 
3T3 were transfected with the mutant versions of  p85αPI3K.  Figure 15B 
shows the result of the lipid kinase assay performed on the mutant enzyme. In 
p85A expressing cells cAMP did not activate PI3K, on the contrary in p85D 
expressing cells the basal activity was slightly higher compared to p85A. 
Moreover, the serine 83 substitution did not significantly affect PI3K activity 
induced by PDGF. 
Taken together these data indicate that cAMP induces PI3K activity 
through serine 83 phosphorylation. 
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Figure 15: PI3K in vitro activity assay. NIH were transfected with p85αPI3K-Flag 
encoding vectors. 24h after transfection cells were starved for 16h.(A) p85WT expressing cells 
were treated with or without 200µM CPT-cAMP for 10 min after a 30 min pretreatment with 
or without 10 µΜ Η89. The cell lysates were immunoprecipitate with the anti-Flag antibody. 
The immunoprecipitates were divided into 2 aliquots. One was analyzed by western blot with 
anti-p85PI3K antibody (bottom panel) and the other one was used for the activity assay (upper 
panel). The histogram shows the quantitative analysis from 3 independent experiments. (B) 
p85A or D expressing cells were treated 10 min with 200µM CPT-cAMP or 15 min with 
100ng/mL PDGF. Cellular extracts were immunoprecipitated with anti-Flag antibody and 
divided into 2 aliquots. One of these was analyzed by western blot (bottom panel) and the other 
was used for the activity assay (upper panel). The histogram is the mean of the quantitative 
analysis from 3 independent experiments. 
 
3d. Phosphorylation of serine 83 on p85αPI3Kalters cAMP induced 
PI3K signalling in vivo 
To verify that cAMP activate in vivo PI3K, NIH 3T3 were serum starved 
for 16 hours and treated 10 minutes with 200µM cAMP in the presence or 
absence of H89. In vivo activity of PI3K can be measured determining the 
phosphorylation state of the downstream targets, such as AKT and GSK 
(Marte and Downward, 1997; Rameh and Cantley, 1999). Figure 16A shows 
the results of anti-P-AKT and anti-P-GSK antibodies. cAMP-induced 
phosphorylation of both proteins in a PKA dependent manner, since it was 
reversed by H89. The total amount of protein was comparable in all the 
samples, as shown by anti-AKT western blot (bottom panel). 
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Figure 16 Activation of PI3K-AKT pathway in response to cAMP. (A)NIH 3T3 were 
serum straved 16h and successively treated 10 min with or without 200 µM CPT-cAMP 
following a 30 min treatment with or without 10 µM H89. Total lysates were analyzed by 
western blot with anti- PGsk, -Gsk and -AKT antibodies.  (B) Serum starved p85WT or mutant 
expressing cells were treated 10 or 90 min with or without 200 µM CPT-cAMP. total lysates 
were analyzed by western blot with anti-PAKT and –AKT antibodies. (C) The white bars 
represent the basal P-Gsk/Gsk ratio in p85WT or mutant expressing cells, the black bars 
represent the same ratio in cells treated 10 min  200µM CPT-cAMP. These results are the 
average of 3 independent experiments. 
 
To test that the effects of cAMP on PI3K in vivo activity were induced by 
serine 83 phosphorylation, NIH 3T3 were transfected with p85WT or mutant 
encoding vector. 36 hours later, the cells were serum-starved for 16 hours. 
Successively, protein lysates were separated on SDS-PAGE and analyzed by 
western blot with anti-P-AKT, -AKT,-P-GSK and –GSK antibodies.  
Figure 16B shows the time course of activation of AKT in the transfected 
cells. In p85WT expressing cells cAMP activated AKT at 10 minutes, this 
effect was lost at 90 minutes. In p85A expressing cells the response to cAMP 
was absent. On the contrary, in p85D expressing cells the basal activity was 
higher compared to the p85WT expressing cells and the activation persisted up 
to 90 minutes. Similar results were obtained analyzing the P-GSK/GSK ratio 
(Fig. 16C). 
Taken together the data presented indicate that cAMP-PKA phosphorylates 
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the serine 83 of p85αPI3K, stimulating the formation of the Ras/PI3K complex. 
The association between these molecules triggers the activation of the PI3K-
AKT pathway which results in inhibition of apoptosis and G1 arrest. 
 
4. Biological effects of the phosphorylation of p85αPI3K TSH-cAMP 
dependent cells: FRTL5 and NTCRII 
Ciullo et al. in 2001 demonstrated that the association between PI3K and 
Ras was essential for the G1-S transition in thyroid cells FRTL5. Considering 
the data presented above concerning the role of serine 83 phosphorylation in 
the formation of Ras/PI3K complex and the regulation of cell survival and 
proliferation in NIH 3T3, we investigated the possibility that serine 83 was a 
key regulator of cAMP effects also in cAMP-dependent cells. 
The following experiments were performed in thyroid cells FRTL5 and 
NTCRII cells. FRTL5 cells proliferate in response to TSH, an hormone who 
activates a Gs coupled receptor (see Background). NTCRII cells are modified 
NIH 3T3 fibroblasts that became TSH-cAMP dependent. Porcellini et al. in 
2003 showed that NIH 3T3 expressing both TSH receptor and the PKA 
regulatory subunit RIIβ proliferated in dependence of TSH-cAMP, 
recapitulating the characteristics of thyroid cells (Fig. 17). 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Effect of TSH on cell proliferation on engineered NIH 3T3. The 
expression of TSHR (T6321) or RIIβ induces cell death in response to TSH added to the 
culture media, while TSH induces proliferation in NIH 3T3 expressing both TSHR and RIIβ. 
(Porcellini et al., JBC, 2003; 278, 40621-40630) 
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4a. p85A is lethal in TSH-cAMP dependent cells 
FRTL5 cells were co-transfected with a G-418 resistance encoding vector 
and p85WT or mutant encoding vector. 96 hours after the transfection 400 
µg/ml of G-418 was added to the media but very few clones expressing p85A 
survived selection. To test if p85A expression in FRTL5 impaired cell 
survival, we tested the plating efficiency of the various transfected lines.  
5x105 cells were transfected with the G-418 resistance encoding vector and 
the indicated vector. 96 hours after the transfection 400 µg/ml of G-418 was 
added to the media. After 15 days, the G-418 resistant clones were counted. 
Figure 18 shows that the numbers of p85A expressing clones was 
significantly lower than the control and p85WT expressing clones. Moreover, 
the number of p85D expressing clones was slightly higher than the number of 
p85WT expressing clones. 
 
Figure 18: Plating efficiency of p85WT, A or D expressing clones. The ability to form 
G-418 resistant clones was determined by transfecting 5*105 FRTL-5 cells with p85WT, A or 
D expressing vector and selecting the clones in the presence of 400 µg/ml of G-418 for 15 
days. The histogram represents the number of clones obtained, and it is the mean of three 
experiments in triplicate. 
 
The few surviving clones expressing p85A were expressed low levels of 
p85A protein (data not shown). These data indicate that p85A expression 
inhibited growth or/and survival in FRTL5, suggesting that phosphorylation 
of serine 83 of p85αPI3K is a key step in the transmission of survival signals in 
FRTL5. To test this hypothesis, NTCRII cells were transiently transfected 
with p85WT, A or D or control vectors. Cells were grown for 18 hours in the 
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presence or absence of 10mU/mL TSH or 100µM cAMP. It is worth noting 
that the cells were grown in low serum medium (0,5%), because growth 
factors in the serum mask, at least in part, the effects of TSH deprivation 
(Porcellini et al., 2003). The cells were collected and analyzed by TUNEL 
assay (see Materials and Methods). Figure 19 shows that TSH deprivation 
induced apoptosis in NTCRII cells that was reversed by TSH or cAMP. The 
expression of p85WT slightly reduced apoptosis induced by TSH deprivation. 
The expression of p85A, on the other hand, stimulated apoptosis under all 
conditions, while p85D expression protected cells from TSH-cAMP 
deprivation-induced apoptosis.  
 
Figure 19: Effects of serine 83 phosphorylation on TSH-cAMP deprivation induced 
apoptosis in NTCRII cells.  5*105 NTCRII cells were transfected with an empty vector or 
p85WT, A or D encoding vector. Cells were grown in 0,5% serum containing medium with 
or without TSH or cAMP. After 18 hours apoptosis was determined through TUNEL assay 
(see Materials and Methods). The western blot inset show the expression of p85 in all the 
samples, the upper band of the doublet is the exogenous protein. 
 
Taken together these data indicate that phosphorylation of serine 83 of 
p85αPI3K mediates cAMP induced survival both in FRTL5 and NTCRII cells. 
 
4b. Phosphorylation of p85αPI3K is necessary for S-G2/M transition 
To test the role of the phosphorylation of serine 83 of p85αPI3K on cell 
proliferation in TSH-cAMP dependent cells, NTCRII cells were transfected 
with an empty vector or the vector encoding p85WT or mutant versions. 24 
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hours after the transfection, the colture media was replaced with 0,5% serum 
containing medium. 18 hours later, 10mU/mL of TSH were added to the media 
to induce cell cycle entry. Cells were analyzed by BrdU labelling, as described 
in Materials and Methods. Figure 20 shows that only the expression of p85A 
affected cell cycle progression. In particular, p85A expressing cells 
accumulated in S-phase at 270 minutes (left panel). The S-phase arrest of p8A 
expressing cells correlates with the reduction of the number of cells in G2/M 
phase at 270 minutes (right panel).  
 
Figure 20: Effects of serine 83 phosphorylation on cell cycle progression. NTCRII cells 
were transiently transfected with the p85WT, p85A, p85D mutants or with the empty vector 
(control). 24 hours after transfection, the cells were starved in 0,5% serum containing medium. 
18 hours later cells were induced with 10 mU/ml TSH. BrdU incorporation was assayed by a 
pulse-chase experiment. Cells were labeled for 30 min with BrdU and harvested at 0, 90 and 
270 min. DNA content was determined by propidium iodide stainig. Cells were subjected to 
FACS analysis for bivariate-analysis of DNA content versus BrdU. 
  
We also monitored EGF-induced proliferation, since NCTRII cells in the 
presence of serum respond to EGF. p85A affected selectively cAMP-TSH 
induced proliferation but not the EGF induced proliferation (data not shown, 
(De Gregorio et al., 2006). These data indicate that phosphorylation of serine 
83 is necessary for cell cycle progression. 
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 5. Molecular mechanisms affected by phosphorylation of serine 83 of 
p85αPI3K in FRTL-5 and NTCRII cells 
As in NIH 3T3, cAMP induced the binding of Ras to PI3K, containing 
p85WT but not p85A (De Gregorio et al., 2006). The formation of this 
complex was tested both in FRTL5 or NTCRII cells, respectively stably or 
transiently expressing p85WT or mutant versions. This indicates that the same 
molecular mechanism, i.e., stimulation of the complex PI3K/Ras, exerts 
opposing effects: cell proliferation in TSH-cAMP dependent cells and G1 
arrest in NIH 3T3. One explanation of this paradox may involve the differential 
expression of RII isoforms in the cell lines analyzed. Both NTCRII and 
FRTL5, in fact, express RIIβ, while this protein is present at low level, if not 
absent, in NIH 3T3 fibroblasts (Porcellini et al., 2003).  
 
5a. Phosphorylated p85αPI3K interacts with RIIβ  
To verify if RIIβ influences the biological effects of serine 83 
phosphorylation, the binding between RIIβ-PKA and PI3K has been tested. 
p85WT, A or D have been transiently expressed in NTCRII cells. 24 hours 
after the transfection, cells were serum starved for 6 hours before the treatment 
with 10mU/mL TSH (20 minutes). Cell lysates were incubated in vitro with 
GST or GST-RIIβ (Grieco et al., 1996). Figure 21 shows the western blot with 
anti-Flag, -GST and -phosphoserine (P-Ser) antibodies on the bound proteins 
(pull down assay). p85WT formed a complex with RIIβ following incubation 
with TSH. The substitution S83A abolished the binding, while the substitution 
S83D determined constitutive (in the absence of cAMP) binding 
RIIβ/p85αPI3K.  
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Figure 21: GST pull down in NTCRII cells. NTCRII cells were transiently transfected 
with the indicated vectors. Serum starved cells were treated 20 minutes with 10mU/mL TSH. 
Cell lysates were incubated with the indicated recombinant proteins. The samples were 
separated on SDS-PAGE and analyzed by western blot with the indicated antibodies. 
 
Moreover, the anti-P-Ser western blot shows that p85WT bound to RIIβ 
was phosphorylated, and the phosphorylation was on serine 83 since p85D 
bound RIIβ without being phosphorylated. 
In order to confirm that TSH induced RIIβ binding to p85αPI3K via cAMP, 
the GST pull down assay was performed on NTCRII cells transfected with 
p85WT, A or D and treated with cAMP, instead of TSH. Figure 22 shows the 
western blot with anti-Flag and anti-GST on the bound proteins.  
 
           
 
 
 
Figure 22: GST-RIIβ pull down in NTCRII expressing p85WT or mutant treated with 
cAMP. NTCRII cells were transiently transfected with p85WT (Flag-p85), p85A or p85D. 24 
hours after transfection cells were serum starved in 0,5% serum. After 6 hours cells were 
treated with 100µM cAMP for 15 minutes. Cell lysates were incubated in vitro with GST-
RIIβ or GST (see Materials and Methods). The pellets of the pull down were separated on 
SDS-PAGE and analyzed by western blot with the indicated antibodies.  
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Also cAMP stimulates the binding of p85WT to GST-RIIβ but not of p85A, 
the binding of p85D instead was constitutive. 
To test if the binding between the two proteins was direct, p85WT or A 
was transiently expressed in NTCRII. Protein lysates from cAMP induced 
cells were immunoprecipitated with anti-Flag antibody and p85αPI3K was 
eluted with 0,1M glycine pH 3,5. The eluted proteins were used for the GST-
RIIβ pull down assay. Figure 23 shows that cAMP induced the binding to 
RIIβ οf p85 WT, not of the mutated version, p85A.  
 
 
Figure 23: GST-RIIβ pull down on immunoprecipitated p85WT or A. Exogenous 
p85PI3K was immunoprecipitated with anti-FLAG antibody from NTCRII cells transfected with 
p85WT or p85A and exposed to 100 µM 8BrcAMP for 15 min. The immunoprecipitates were 
extensively washed in RIPA buffer containing 1% Triton X-100 -0.1% SDS and purified by 
elution with 0.1M glycine pH 3.5. Input indicates the eluted fraction; +glycine represents the 
pellet after elution. The purified p85PI3K was incubated in vitro with GST-RIIβ in a pull-down 
experiment as described in Materials and Methods. 
 
Together these data indicate that phosphorylation of serine 83 in p85αPI3K is 
important for the binding to RIIβ-PKA. This results, possibly, in the anchoring 
of PKA under the plasma membrane and the phosphorylation of a particular 
subset of substrates.  
 
5b. Phosphorylation of serine 83 on p85αPI3Kalters cAMP induced 
PI3K activity both in vitro and in vivo 
To determine if phosphorylation of p85αPI3K correlates with an increase of 
activity of PI3K, as in NIH 3T3, NTCRII cells were transiently transfected 
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with p85WT or A. Cells were then serum starved and induced 15 minutes with 
cAMP. 
Exogenous p85αPI3K was immunoprecipitated with the anti-Flag antibody 
and the immunoprecipitates divided into two aliquots: one aliquot was used to 
test in vitro lipid kinase activity and the other to control the 
immunoprecipitation efficiency. 
Figure 24A show that cAMP activated p85WT- p110αPI3K but not p85A- 
p110αPI3K. Moreover, the phosphorylation of p85αPI3K did not affect the EGF-
induced PI3K activity (Fig. 24B). 
 
Figure 24: Effect of serine 83 substitution on in vitro PI3K activity. NTCRII cells were 
transiently transfected with p85WT or mutant. Cells were serum starved for 8 hours and treated 
20 minutes with 10mU/mL of TSH (A) or 100nG/mL of EGF (B). The in vitro lipid kinase 
assay was performed as described in Materials and Methods. The histograms on the right 
represent the mean of the cpm counted on three independent experiments. 
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 These data were confirmed in vivo by determining the level of 
phosphorylation of AKT in NTCRII cells transiently transfected with p85WT 
or mutant versions and treated with TSH. 
Figure 25 shows that p85A expressing cells fail to activate AKT at all time 
points considered. On the other end, expression of p85D slightly amplified 
TSH signaling. P-AKT levels were, in fact, higher in p85D expressing cells 
than in the controls both at 0 and 5 minutes. These results confirm that 
phosphorlation of p85αPI3K was necessary to activate PI3K through cAMP-
PKA pathway. 
 
 
Figure 25: Effect of serine 83 phosphorylation on AKT activation in NTCRII cells. 
NTCRII cells were transfected with the indicated vector, 30 hours later the normal medium 
was replaced with a low serum medium (0,5% serum). After 18 hours cells were treated with 
10mU/mL TSH for the indicated time. Protein lysate were analyzed by western blot with anti-
P-AKT and –AKT antibodies. The histogram in B is the mean of three independent 
experiments.   
 
6. cAMP-PKA amplifies estrogen binding and signaling to PI3K  
Considering that PI3K is essential also in estrogen mediated AKT 
activation (Simoncini et al., 2000; Castoria et al., 2001) and that p85αPI3K was 
efficiently phosphorylated in MCF-7 cells (Fig. 10A) it was possible that serine 
83 phosphorylation was required for estrogen signaling. To verify this 
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hypothesis MCF-7 cells were made quiescent using charcoal-treated serum and 
medium lacking phenol-red for 3 days. Quiescent cells were transiently 
transfected with p85WT or mutant, after 24 hours, the cells were treated 3 
minutes with 10 nM E2. Cell lysates were separated on SDS-PAGE and 
analyzed by western blot with anti-P-AKT, -AKT and –p85 antibodies. Figure 
26A shows that estrogen activated AKT both in cells transfected with the 
empty vector (nt) and in p85WT expressing cells. The expression of p85A 
abolished the induction of AKT phosphorylation. Conversely expression of 
p85D stimulated AKT phsphorylation.  
 
Figure 26: Estrogen signaling to AKT in MCF-7 cells transfected with p85WT or 
mutant. MCF-7 cells were made quiescent using charcoal-treated serum and medium without 
phenol-red for 3 days. Quiescent cells were transfected with the indicated vector. A) 
Transfected cells were treated without or with 10 nM E2 for 3 minutes. Protein lysates were 
analyzed by western blot with the indicated antibodies. B) Transfected cells were treated with 
or without: 10 nM E2 (3 minutes), 10µM H89 (30 minutes), 200µM CPT-cAMP (10 minutes). 
Protein lysates were immunoprecipitated with anti-Flag antibody and immunoprecipitates 
analyzed by western blot with anti-p85 and –ERα antibodies. 
 
Since estrogens activate PI3K-AKT pathway through the direct binding of 
the receptor to p85αPI3K (Castoria et al., 2001) it was possible that 
phosphorylation of serine 83 was required for p85αPI3K binding to ERα. 
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In order to test this hypothesis, quiescent MCF-7 cells were transiently 
transfected with p85WT or mutant. 24 hours later, cells were treated with E2, 
H89 and/or cAMP. Protein lysates were immunoprecipitated with anti-Flag 
antibody and analyzed by western blot with anti-p85 and -ERα antibodies. 
Figure 26B shows that estrogen induced p85WT binding to the receptor, cAMP 
on its own did not induce the binding but amplified estrogen-stimulated 
binding. In fact, the amount of receptor bound to p85αPI3K was significantly 
higher in cAMP and estrogen-treated cells than in cells exposed to estrogen 
alone. Moreover, the binding was PKA-dependent, since H89 inhibited the 
effects of estrogens. 
cAMP-PKA modulates ERα- p85αPI3K binding through  the 
phosphorylation  of p85αPI3K. In fact p85A failed to bind the receptor in all the 
conditions considered. Once more, it is worth noting that the phosphorylation 
of serine 83 of  p85αPI3K is absolutely necessary to mediate cAMP-PKA 
effects, but it is not sufficient. In fact, p85D binding to ERα in E2 treated cells 
was inhibited by H89.  These data indicate that phosphorylation of serine 83 is 
required for the binding of p85αPI3K to ERα and the consequential activation of 
PI3K-AKT, but it still requires PKA, because these events are H89 sensitive. It 
is worth noting that ΕRα itself may be a PKA substrate (Cui et al., 2004; 
Michalides et al., 2004). These observations suggest the possibility that the 
receptor has to be phosphorylated by PKA to efficiently bind p85α. 
 
 
 
                                                                                               57
 
Discussion 
 
The data presented here indicate that phopshorylation of p85αPI3K on serine 
83 is a critical step in the cAMP-PKA signaling. Biological effects of cAMP 
and PKA on cell cycle and growth have been extensively studied (Pastan et al., 
1975; Lee et al., 1998; Ariga et al., 2000; Stork and Schmitt, 2002) but the 
molecular mechanism(s) underling their action are not yet defined. Our data 
may shed light on cAMP mediated phenotypes and may provide some 
mechanistic insights into transduction signalling in a variety of cell types. 
1. cAMP-PKA selectively influences Ras signaling 
Previous data indicate that cAMP inhibits Raf1 association with Ras and  
down-regulates the MAPK pathway through two different mechanisms. 
The first is cAMP, but not PKA, dependent. In  fact cAMP stimulates 
directly EPAC, a guanine nucleotide exchange factor for the Ras-like small 
GTPases (Rap1 and Rap2) (Bos, 2003). Rap1 binds Raf1 and inhibits its kinase 
function (Hu et al., 1999).  The importance of Rap1 mediated regulation of 
Raf-1 is confirmed by the complementary action of insulin. In fact, insulin, in 
the absence of cAMP-PKA, decreases Rap1 bound to Raf1 and increases the 
association Ras-Raf1, with a concomitant stimulation of Raf1-MEK-ERK 
cascade (Okada et al., 1998). The second mechanism is PKA dependent, PKA 
in fact phosphorylates serines 43 and 259 in Raf1. Phophorylation of serine 43 
decreases the binding to Ras, while serine 259 appears to be the sole target for 
PKA inhibition of ERK1/2 (Dhillon et al., 2002).  
The inhibition of Raf-1 signalling does not necessarily correspond to 
MAPK inhibition by cAMP. In fact cAMP may stimulate rather than inhibit 
MAPK (Stork and Schmitt, 2002; Norum et al., 2003). Our data indicate that 
the major target of cAMP-PKA action is PI3K. Ciullo et. al in 2001 showed 
that Ras binding to PI3K increases when the cells were exposed to cAMP. 
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Moreover, the formation of this complex was dependent on PKA activity, since 
H89 reversed cAMP-induced association PI3K/Ras.  
The results reported here indicate that PKA phosphorylates serine 83 of 
p85αPI3K and this event is necessary for the binding to Ras, although not 
sufficient. This has been shown in NIH 3T3 and confirmed in TSH-dependent 
cells (De Gregorio et al., 2006), suggesting that it is a general, not a tissue 
specific mechanism. Our data indicate that phosphorylation of serine 83 in 
p85αPI3K stabilized the binding with p110αPI3K, resulting in stimulation of the 
enzymatic activity both in vivo and in vitro (Figs 14, 15 and 24). Stabilization 
of p110αPI3K-p85αPI3K complex is important for two reasons: 1. It may 
facilitate translocation to the cellular membrane (see Background); 2. It 
increases local specific activity. We suggest that phosphorylated p85αPI3K 
associates more efficiently to p110αPI3K, stabilizes the enzyme and localizes to 
the membrane. This results in an increased binding of PI3K to Ras and to the 
activation of the PI3K-AKT pathway. 
 
2. cAMP-PKA regulates cell cycle progression through p85αPI3K 
phosphorylation 
cAMP inhibits proliferation in NIH 3T3. In fact the phosphorylation of 
p85αPI3K leads to G1 arrest in fibroblasts, as shown by transfecting the mutant 
p85D. On the contrary, preventing the phosphorylation (p85A), NIH 3T3 cells 
become resistant to cAMP-induced G1 arrest (Fig. 12) . A different effect was 
observed in TSH-dependent cells. The phosphorylation of p85αPI3K is in fact 
essential for a correct progression of the cells through S and G2/M phases (Fig. 
20). How can the same phosphorylation lead to opposing phenotypes? 
It is worth noting that NIH 3T3 fibroblasts display a very short cell cycle, 
approximately 24 hours, to complete 1 cycle. This implies a short G1. On the 
other hand, TSH-dependent cells display a 48 hours long cell cycle with an 
extended (ca. 36 h) G1. We suggest that cAMP-PKA regulates the length of 
G1. This effect is not detectable in TSH-dependent cells since they do not 
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proliferate in the absence of TSH or cAMP and in their presence the cells show 
a long G1. Moreover, cAMP activates PI3K-AKT pathway and one of the 
terminal targets of AKT is mTOR. mTOR induces protein synthesis that results 
in cell growth (Garcia et al., 2006). On the other side, in S. cerevisiae iper-
activation of cAMP-PKA can compensate the inactivation of PI3K-mTOR 
signalling (Rohde et al., 2004; Zurita-Martinez and Cardenas, 2005). This 
indicates that cAMP-PKA induces cell growth in yeast, as well as mTOR 
stimulation. Cell growth depends on protein synthesis and cell size. Both these 
activities are robustly stimulated by cAMP-PKA (Zurita-Martinez and 
Cardenas, 2005).  We believe that the increase of the length of G1 in NIH 3T3 
by cAMP mimics the effects seen in thyroid cells, where a long G1 is 
accompanied by an increase in the cell size. TSH and cAMP are the driving 
force that accounts for PI3K stimulation and increase in cell size that ultimately 
represents the trigger of S phase (Baroni et al., 1992). This is briefly outlined 
in Fig.27.  
 
Figure 27: Model of the role of serine 83 phosphorylation. PKA phosphorylating serine 
83 of p85αPI3K stabilizes the ternary complex Ras-PI3K. This triggers to the activation of AKT 
pathway. It leads to: cell survival, growth (protein synthesis) and proliferation depending on 
the cell type. 
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3. cAMP cytoprotective action requires serine 83 phopshorylation 
cAMP protects cells from apoptosis induced by different signals in different 
cell types (Affaitati et al., 2003). In this study the resistance to anoikis has been 
evaluated. This apoptotic pathway is triggered by the loss of cell-matrix signals 
and it is highly dependent on PI3K. This system allowed us to define the role 
of serine 83 phopshorylation without the interferences of other survival 
pathway. The result was that phosphorylation of serine 83 was critical for 
cAMP mediated protection from anoikis. Moreover p85D expression replicated 
the effects of cAMP, at least in part (Fig. 11). This suggests that the 
phosphorylation of serine 83 of p85αPI3K is the main player of cAMP 
cytoprotective signals. 
The function of phosphorylated serine 83 was essential in TSH-dependent 
cells.  In fact, the absence of TSH or cAMP induced apoptosis in p85WT but 
not p85D-expressing cells. Moreover thyroid and thyroid-like cells undergo 
apoptosis when expressed p85A, also in the presence of TSH (Figs 18 and 19) 
This further indicates that p85αPI3K is a key player in TSH-cAMP induced 
survival. 
4. PKA-RIIβ expression switches cells from cAMP-dependent 
proliferation to cAMP-dependent arrest 
Different isoforms of PKA exist, depending on the characteristics of the 
regulatory subunit (Feliciello et al., 2001). We can distinguish RI and RII 
subunits, the first has a higher sensitivity to cAMP. This indicates that RI-PKA 
responds to low level of cAMP while RII-PKA to high level of intracellular 
cAMP. Thyroid cells express high level of PKA-RII, and in particular PKA-
RIIβ. Moreover, NIH 3T3 cells expressing TSH receptor but not RIIβ, do not 
proliferate in response to TSH. Only cells expressing in the meantime TSHR 
and RIIβ become TSH dependent cell for growth (Porcellini et al., 2003). This 
indicates that RIIβ levels distinguish cAMP-dependent cells from independent 
cells.  
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Here we show that RIIβ binds phosphorylated p85αPI3K and 
phosphorylation on serine 83 is the only requirement to this event, since p85D 
constitutively bind RIIβ (Figs 21 and 22). This association anchors PKA at the 
cellular membrane, determining a highly localized kinase activity (Feliciello et 
al., 2001). 
 
5. cAMP-PKA phosphorylates p85αPI3K and amplifies estrogens 
signaling 
The data presented in this study indicate that cAMP cooperates with 
estrogens in the stimulation of AKT. Moreover, this effect is dependent on 
p85αPI3K phosphorylation. In fact, p85A was unable to bind the estrogen 
receptor and p85A expressing cells did not activate AKT in response to 
estrogens. On the other hand, the substitution S83D amplified the association 
ERα-p85αPI3K induced by estrogens. Moreover, p85D expression enhanced 
estrogens mediated activation of AKT. These observations indicate that 
phosphorylation of serine 83 is essential for estrogens signaling. Our data also 
indicate that this step is necessary but not sufficient, because p85D expressing 
cells still respond to cAMP to amplify AKT signaling (Fig. 26).  PKA can 
phosphorylate the receptor itself (Cui et al., 2004; Michalides et al., 2004), and 
this phosphorylation may be required for fully activation of the ERα-p85αPI3K 
circuit. Considering that estrogens activate the adenylyl cyclase (Aronica et al., 
1994) and H89 prevents the association ERα-p85αPI3K, it is likely that PKA-
dependent phosphorylation occurs even in cells treated only with estrogens, 
and that the bound p85αPI3K is only the phosphorylated form. This may explain 
why p85A acts as a negative dominant.  
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Conclusions 
The data presented above have broad implications since they point to p85αPI3K 
as the physical link between different pathways: cAMP, Ras and virtually all 
the receptors that can bind PI3K (i.e. ERα), as schematically shown in Figure 
28.  
Moreover, the mechanisms described are relevant both in cAMP-dependent 
and –independent cells and contribute to explain the pleiotropic nature of the 
cAMP-PKA circuit in different cell types and under different conditions.  
 
 
Figure 28: Amplification of estrogens and Gs protein-coupled receptors (GPCR) 
signaling to PI3K. A scheme outlining the effects of cAMP-PKA activation by Gs protein 
coupled receptors on PI3K signaling by estrogens. The pathway illustrated may link several 
receptor G protein coupled to estrogens and Ras-PI3K signals. 
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p85 regulatory subunit of PI3K mediates cAMP–PKA and estrogens
biological effects on growth and survival
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Cyclic adenosine 3050 monophosphate (cAMP) and protein
kinase A (PKA) cooperate with phosphatidylinositol 30
kinase (PI3K) signals in the control of growth and
survival. To determine the molecular mechanism(s)
involved, we identified and mutagenized a specific serine
(residue 83) in p85aPI3K, which is phosphorylated in vivo
and in vitro by PKA. Expression of p85aPI3K mutants
(alanine or aspartic substitutions) significantly altered the
biological responses of the cells to cAMP. cAMP
protection from anoikis was reduced in cells expressing
the alanine version p85aPI3K. These cells did not arrest in
G1 in the presence of cAMP, whereas cells expressing the
aspartic mutant p85D accumulated in G1 even in the
absence of cAMP. S phase was still efficiently inhibited by
cAMP in cells expressing both mutants. The binding of
PI3K to Ras p21 was greatly reduced in cells expressing
p85A in the presence or absence of cAMP. Conversely,
expression of the aspartic mutant stimulated robustly the
binding of PI3K to p21 Ras in the presence of cAMP.
Mutation in the Ser 83 inhibited cAMP, but not PDGF
stimulation of PI3K. Conversely, the p85D aspartic
mutant amplified cAMP stimulation of PI3K activity.
Phosphorylation of Ser 83 by cAMP–PKA in p85aPI3K
was also necessary for estrogen signaling as expression of
p85A or p85D mutants inhibited or amplified, respec-
tively, the binding of estrogen receptor to p85a and AKT
phosphorylation induced by estrogens. The data presented
indicate that: (1) phosphorylation of Ser 83 in p85aPI3K is
critical for cAMP–PKA induced G1 arrest and survival in
mouse 3T3 fibroblasts; (2) this site is necessary for
amplification of estrogen signals by cAMP–PKA and
related receptors. Finally, these data suggest a general
mechanism of PI3K regulation by cAMP, operating in
various cell types and under different conditions.
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Introduction
Cyclic adenosine 3050 monophosphate (cAMP) regulates
the growth of many cells types (Pastan et al., 1975).
Although cAMP can promote the growth of some cells,
such as Swiss 3T3 fibroblasts and thyrocytes (Lee et al.,
1998; Ariga et al., 2000), it inhibits proliferation in
most cells (Magnaldo et al., 1989). However, the precise
mechanism by which cAMP inhibits cell cycle entry
and progression remains undefined (Houslay and
Kolch, 2000). cAMP prevents cells from entering S
phase and arrests the cells in G1 (Kato et al., 1994).
Furthermore, cAMP inhibits proliferation stimulated by
either G protein-coupled receptors or receptor tyrosine
kinases (Magnaldo et al., 1989), suggesting that it
targets a signaling pathway that is central to cell cycle
progression.
Stimulation of growth by cAMP–protein kinase A
(PKA) in selected cell types, as thyroid cells, is tightly
dependent on Ras and phosphatidylinositol 30 kinase
(PI3K) (Ciullo et al., 2001). Also, cAMP and PKA are
powerful survival signals in several cell types (Affaitati
et al., 2003). To date the mechanism(s) and the relevant
players mediating cAMP effects on growth and survival
are not completely known.
We have previously shown that cAMP and PKA
regulate Ras signaling, by selectively stimulating Ras–
PI3K complex. Also, we have found that p85aPI3K was
an efficient PKA substrate in vitro (Ciullo et al., 2001).
Here we report that Ser 83 in the p85aPI3K is
phosphorylated in vivo by PKA and that the corre-
sponding mutants (p85A or p85D) inhibit or amplify
cAMP biological effects on growth and survival. This
site is also relevant for the interaction of p85aPI3K with
estrogen receptor a, as the mutants inhibit or amplify
estrogen signaling to PI3K. Finally, we demonstrate that
cAMP in the absence of serum stimulates PI3K and that
p85aPI3K mutants selectively interfere with cAMP stimu-
lation of PI3K activity.
These data provide a molecular framework that
explains the synergism between cAMP and different
types of receptors, and add another level of com-
plexity to the regulation of PI3K and Ras p21 by
cAMP–PKA.
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Results
PKA phosphorylates Ser 83 in p85aPI3K
p85a subunit of PI3K can be efficiently phosphorylated
by PKA in vitro (Ciullo et al., 2001). A possible PKA
target sequence is Ser 83, which is highly conserved
in evolution and is preceded by basic residues in
bovine/human (KKIS) and mouse/rat (KRIS)
sequences.
To determine the relevance of this site in vivo, we have
substituted Ser 83 with alanine (p85A) to prevent
phosphorylation or with aspartic acid (p85D) to mimic
the phosphorylated residue. The tagged recombinant
proteins were transiently expressed in HeLa or NIH3T3
cells and immunoprecipitated with anti-flag antibody.
Immunoprecipitates were incubated in vitro with pur-
ified catalytic PKA subunit in the presence of [32g-
P]ATP. p85aPI3K wild type was efficiently phosphory-
lated by PKA whereas p85A was not, indicating that Ser
83 was the site phosphorylated by PKA in vitro
(Figure 1a). PKA-phosphorylated p85aPI3K was also
identified in vivo in breast cancer cells MCF7 extracts
immunoblotted with an antiphosphoserine antibody.
Figure 1b shows that p85aPI3K, not p85A, was recognized
by the phosphoserine antibody in extracts of MCF7 cells
treated with cAMP. Figure 1c shows the same experi-
ment performed in NIH3T3 cells expressing p85aPI3K
and p85A. The p85A protein was not recognized by the
antiphosphoserine antibody. Phosphorylation of
p85aPI3K was prevented by incubating the cells with the
PKA kinase inhibitor H89 (Figure 1c). The endogenous
protein p85aPI3K was also phosphorylated in NIH3T3
cells stimulated with cAMP. Phosphorylation was
inhibited by pretreating the cells with H89 (Figure 1d).
Taken together these data indicate that PKA phos-
phorylates p85aPI3K at Ser 83.
p85aPI3K mutants alter cAMP cytoprotection and growth
inhibition
To test the biological relevance of Ser 83 phosphoryla-
tion of p85aPI3K, we determined in mouse fibroblasts the
rate of anoikis, a specific apoptotic pathway triggered by
loss of cell adhesion to the extracellular matrix (Frisch
and Francis, 1994; Khwaja et al., 1997). We co-
transfected NIH3T3 cells with a GFP encoding vector
and the wild type or the mutant versions of p85aPI3K
(Figure 2a and b). At 48 h after transfection, the cells
were plated on 2% agarose in a medium containing
0.1% calf serum in presence or absence of 200 mM
cAMP. After 5 h, we determined the fraction of
apoptotic cells by fluorescent activated cell sorter
(FACS) analysis. Figure 2b shows that treatment with
cAMP significantly reduced the number of apoptotic
cells. cAMP cytoprotection was abolished by wortman-
nin, a PI3K inhibitor (data not shown and Khwaja
et al., 1997). Expression of wild-type p85aPI3K amplified
cAMP response (see n in Figure 2b), whereas expression
of p85A completely eliminated cAMP amplification,
displayed by wild-type p85aPI3K (Figure 2b). Cells
expressing p85D, on the other hand, were significantly
more resistant to anoikis in the absence of cAMP (see nn
in Figure 2b). The low response to cAMP of these cells
was probably dependent on the low levels of p85D
protein (Figure 2a). These data indicate that p85aPI3K
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Figure 1 Phosphorylation in vivo and in vitro of Ser 83 in p85aPI3K by cAMP–PKA. (a) In vitro phosphorylation of wild-type p85aPI3K
or p85A. HeLa cells were transiently transfected with p85aPI3K-flag wild type or p85A; 48 h after transfection, cell lysates were
immunoprecipitated with non-immune IgG or anti-flag antibody for 15 h. A/G bound immunoprecipitates were in vitro
phosphorylated with cPKA as described in Material and methods. Sample aliquots were run on SDS–PAGE and subjected to
immunoblot (upper panel) or autoradiography (bottom panel). (b) In vivo phosphorylation of wild-type p85aPI3K or p85A. MCF7 cells
were made quiescent using charcoal-treated serum and medium lacking phenol-red for 3 days. Quiescent cells were transfected with
p85aPI3K or p85A. At 24 h after the transfection cells were treated with 100 mM cAMP. Protein lysates were immunoprecipitated with
anti-flag antibody for 15 h, separated on 10% SDS–PAGE and immunoblotted with anti-p85PI3K (upper panel) or antiphosphoserine
(lower panel) antibodies. The arrow indicates p85aPI3K band. (c) NIH 3T3 were transfected with p85aPI3K or p85A. At 24 h after
transfection, the cells were treated with 100 mM cAMP in the presence or absence of the protein kinase A inhibitor, H89 (10mM). In
parallel cultures (d) un-transfected (nt) NIH3T3 cells, starved in DMEM 0.1% calf serum for 16 h, were treated with 100 mM cAMP for
10min in the presence or absence of 10mM H89. Cell lysates were immunoprecipatated with anti-p85a antibody and immunoblotted
with anti-p85a (upper panel) or anti-phosphoserine (lower panel) antibodies.
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mediates cAMP inhibition of anoikis and that phos-
phorylation of Ser 83 is an important signal for cAMP-
induced-survival.
To test if p85aPI3K mediated also cAMP inhibition of
growth in mouse NIH3T3 fibroblasts, we analysed the
biological effects of p85aPI3K mutants on growth arrest
induced by cAMP. NIH3T3 fibroblasts were cultured in
low serum in the presence or absence of cAMP. Under
these conditions, cAMP induced a robust and reversible
inhibition of cell growth by accumulating the cells in G1
phase and reducing the fraction of cells entering S phase
(see n in Figure 2c and d). Cells expressing p85A did not
efficiently arrest in G1 in the presence of cAMP
(Figure 2c). Conversely, in cell lines expressing the
aspartic mutant, cAMP response was lost and the
fraction of cells accumulating in G1 was significantly
higher than in cells expressing p85A (see nn in
Figure 2c). The fraction of cells arrested in S phase in
the presence of cAMP was robustly stimulated in the
control and cells expressing the wild-type p85aPI3K (see n
in Figure 2d). Cells expressing the mutant versions of
p85aPI3K did not respond to cAMP and the fraction of
cells transiting S increased (see Figure 2d, p85Annn) or
decreased (see Figure 2d, p85Dnnn) relative to control
or wild-type p85aPI3K cells. These data indicate a higher
(p85D) or lower rate of G1 arrest (p85A) of these cell
lines, independently on cAMP presence in the medium.
The high statistical significance of S phase values,
relative to G1, is due to the lower value of S phase cell
fraction. To discriminate more precisely the effects of
cAMP in G1 or S phases in cells expressing p85aPI3K
mutants, we performed a kinetic analysis of the cell cycle
by labeling the cells with BrdU. Under these conditions,
the entry and the progression in S phase of transfected
cells can be precisely determined. Figure 2e shows that
p85A or p85D did not alter S phase progression,
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Figure 2 Phosphorylation of p85aPI3K Ser 83 mediates cAMP biological effects on growth and survival. NIH3T3 cells were transiently
transfected with p85aPI3K-flag wild type or mutant versions. A GFP expression vector encoding green fluorescence protein was used as
reporter. At 48 h after transfection, cells were plated on 2% agarose in DMEM 0.1% CS without or with cAMP 200 mM for 5 h and the
fraction of apoptotic cells was determined by FACS analysis. (a) Extracts of transfected cells immunoblotted with anti-p85aPI3K
antibody. Exogenous p85aPI3K is represented by the upper band in the doublet. (b) Quantitative analysis of FACS data. White and
black columns represent, respectively, untreated or cAMP-treated samples. The data are the mean of four independent experiments; n
indicates Pp0.01 comparing cell death in the presence of cAMP in all samples. The p85A (ALA) sample is significantly different from
p85aPI3K (WT), but not from CTRL or p85D (ASP). To analyse the growth, NIH3T3 cells were transiently transfected with the
constructs indicated above. At 24 h after the transfection, the cells were serum-starved 15 h and induced into the cycle with 2% serum in
the presence or absence of cAMP (200 mM for 6 h). After 12 h the cells were subjected to FACS analysis. The quantitative analysis of
FACS data relative to G1 phase (c) or S phase (d) was derived from three independent experiments and analysed by Student paired T-
test. Black and gray columns represent respectively untreated or cAMP-treated samples. n indicates Pp0.01 basal versus cAMP;
nnPp0.01 basal p85A versus p85D; nnnPp0.01 basal p85a wild type, A or D-transfected cells versus control plasmid-expressing cells.
(e) Pulse (300)-chase of BrdU incorporation in transfected cell lines in the presence or absence of cAMP. The columns represent the
fraction of labeled cells stained with propidium iodide at 0 (black columns), 90 (gray columns) and 270min (white columns) from the
initial cell cycle induction (10% serum). The data are the mean of three independent experiments.
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although p85A-expressing cells transited S phase very
rapidly, compared to control or p85D expressing lines in
the presence of cAMP. Cells expressing p85A were
unrestrained in G1 in the presence of cAMP and entered
S phase more efficiently than control or p85D-expres-
sing cells. Taken together, these data indicate that Ser 83
in the p85aPI3K is critical for cAMP-induced G1 arrest on
cell cycle progression. Alanine substitution of Ser 83
abolished G1 arrest by cAMP. p85D, on the other hand,
increased the number of cells arrested in G1 in the
absence of cAMP (see nn in Figure 2d).
p85aPI3K (ser83) phosphorylation increases association of
to p21 Ras
We have previously shown that cAMP PKA selectively
increased the association between PI3K and p21 Ras
(Ciullo et al., 2001). As this complex can mediate
cAMP–PI3K effects on growth and survival, we set out
to determine the formation of p21 Ras–PI3K complex in
cells expressing wild-type p85aPI3K or p85A or p85D.
NIH3T3 were transfected with p85aPI3K wild type or
p85A or p85D and 36 h after transfection, the cells were
serum starved for 16 h before 10min treatment with
cAMP. Cell lysates were immunoprecipitated with anti-
flag antibody and then analysed by Western blot with
anti-Ras antibody. In the presence of cAMP, p85aPI3K
wild type efficiently was found associated with p21 Ras.
This association was significantly inhibited in cells
expressing p85A and stimulated in p85D expressing
cells. In the absence of cAMP, Ras–PI3K complex was
barely detectable in all the samples. In p85D-expressing
cells, however, cAMP stimulated robustly association of
PI3K to p21 Ras, suggesting that Ser 83 in p85aPI3K
cooperates with another cAMP–PKA signal to regulate
PI3K association with p21 Ras (Figure 3a and b). We
also tested the effects of H89 on the formation of the
Ras–PI3K complex. H89 treatment reduced the complex
Ras–PI3K to the levels found in p85A-expressing cells
(Figure 3c). These data indicate that under conditions of
cAMP stimulation, the interaction Ras–PI3K is sig-
nificantly favored.
p85aPI3K (Ser 83) phosphorylation selectively amplifies
PI3K signaling by cAMP
To directly test the hypothesis that cAMP stimulation
amplified Ras–PI3K signalling, we stimulated the cells
with cAMP or PDGF and determined AKT and GSK
phosphorylation, downstream targets of PI3K.
Figure 4a shows that cAMP and PKA stimulated the
phosphorylation of AKT and GSKa and that H89
reversed cAMP effects. To test if p85aPI3K mutants
interfere also with other pathways that signal to PI3K,
we determined PDGF stimulation of AKT and ERK1/2,
the two major kinases downstream to PDGFR.
Figure 4b shows that expression of p85A and p85D
did not significantly influence PDGF stimulation of
ERK1/2 or P-AKT accumulation. p85A-expressing
cells, on the other hand, poorly phosphorylated AKT
or GSKa in response to cAMP. Conversely, expression
of p85D increased the basal P-AKT and P-GSKa and
robustly amplified cAMP response (Figure 4c and d).
So far we have analysed the effects of p85aPI3K
variants on indirect effectors of PI3K signaling. To
directly test the relevance of cAMP induced phosphor-
ylation of p85aPI3K on PI3K activity, we have measured
the activity of the enzyme in cells expressing wild type or
the mutant versions of p85aPI3K. We have previously
reported that cAMP in the presence of serum did not
stimulate PI3K activity (Ciullo et al., 2001). As the
presence of serum can mask some important biological
effects of cAMP–PKA (Porcellini et al., 2003) and (De
Gregorio et al., 2006, in press), we carried out the
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Figure 3 cAMP stimulates the formation of PI3K/Ras complex. NIH-3T3 cells were transiently transfected with wild type or mutant
versions of p85aPI3K-flag. At 36 h after transfection, the cells were starved for 16 h in DMEM, 0.1% calf serum and treated with cAMP
200mM for 10min. (a) Cells lysates were immunoprecipitated with anti-flag antibody and blotted with anti-Ras or anti-p85aPI3K
antibodies. (b) The histograms represent the ratio of Ras-p85aPI3K bands in the p85aPI3K immunoprecipitates, derived from three
independent experiments. (c) NIH-3T3 were transiently transfected with wild-type p85aPI3K-flag or p85A. At 36 h after transfection, the
cells were starved for 16 h in DMEM, 0.1% calf serum and treated with cAMP 200mM for 10min in the presence or absence of H89.
Cells lysates were immunoprecipitated with anti-Ras antibody and blotted with anti-Ras or anti-flag antibodies.
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stimulation of transfected cells with cAMP in low serum
(0.2%). Figure 5 shows that cAMP stimulated PI3K
activity. The activation of PI3K was inhibited by
treatment of the cells with the PKA inhibitor, H89.
Moreover, cells expressing p85A did not activate PI3K
in response to cAMP, whereas efficiently activated
PI3K, when treated with PDGF. Conversely, p85D
amplified PI3K activity induced by cAMP and did not
significantly influence PI3K stimulated by PDGF
(Figure 5, lower inset).
To determine if p85A altered the structure of the
protein and inhibited the formation of the PI3K
complex, we tested the ability of in vitro synthesized
p85aPI3K to interact and form a stable complex with
p110aPI3K. Supplementary Figure 1S shows that co-
translated p85aPI3K and p110aPI3K interact very effi-
ciently. When tested under the same conditions, p85A
ability to interact with p110aPI3K was comparable to
that of the wild-type p85aPI3K (Supplementary
Figure 1S). p85D, on the other hand, formed a complex
with p110aPI3K synthesized in vitro, with a higher affinity
than p85aPI3K wild type or p85A. These data indicate
that p85A does not disrupt the folding of p85aPI3K
protein or the ability to interact with p110aPI3K, whereas
p85D induces a conformational change that improves
the interaction with p110aPI3K. As p85D stimulates
cAMP-induced PI3K activity, we suggest that this
conformational change activating the enzyme is
mediated by phosphorylation of p85aPI3K in Ser 83
by PKA.
cAMP–PKA amplify estrogen binding and signaling to
PI3K
PI3K mediates also AKT activation by estrogens
(Simoncini et al., 2000; Castoria et al., 2001). As
p85aPI3K was efficiently phosphorylated by PKA in
MCF7, the breast carcinoma cell line, we asked whether
p85aPI3K phosphorylation on Ser 83 also affected PI3K
interaction with upstream effectors such as estrogen
receptor. Therefore, we analysed the phosphorylation of
AKT stimulated by estrogen. Cells expressing p85aPI3K
wild type or p85A or p85D were treated with estrogens
and stimulation of AKT was monitored with specific P-
AKT antibodies. Figure 6a shows that p85D amplified
AKT phosphorylation induced by estrogens and that
p85A abolished this stimulation. Also, induction of
GSK phosphorylation by estrogens was inhibited by
p85A expression (data not shown).
As estrogen stimulation of AKT was inhibited in cells
expressing p85A, we measured the fraction of the
estrogen receptor a bound to wild type and mutant
versions of p85aPI3K. Figure 6b shows that wild-type
p85aPI3K immunoprecipitated efficiently the receptor.
The binding of estrogen receptor to p85aPI3K was
stimulated by estrogens, as expected. cAMP did not
stimulate the binding per se in the absence of estrogens,
but amplified the action of estrogens on p85aPI3K
binding. H89, a PKA inhibitor, eliminated the binding
of the receptor to p85aPI3K. The p85A protein did not
bind the estrogen receptor in the presence or in the
absence of estrogens. Expression of p85D substituted
Figure 4 Serine phosphorylation of p85 selectively amplifies cAMP signaling to AKT and GSK. (a) NIH3T3 cells were stimulated
with 8-Cl-cAMP (100mM) in the presence or absence of H-89 (10mM) for 10min. Total extracts were prepared and immunoblotted with
the specific antibodies indicated. (b and c) Immunoblots of extracts derived from cells transiently transfected with the p85aPI3K
expression vectors indicated. In (b) the cells were stimulated with PDGF (100 ng/ml) for 15min, 48 h after the transfection; in (c) the
cells were stimulated with 8-Cl-cAMP (100 mM) for 10 and 90min, respectively. (d) The histograms of the pGSKa/GSK ratio, evaluated
by densitometric analysis of Western blot with appropriate antibodies of extracts derived from cells transfected with the indicated
p85aPI!K plasmids and stimulated with (black) or without (white) cAMP (100 mM) for 10min. Basal P-AKT in cells expressing p85D is
lower in (b) than in (c), because the cells were starved 24 h (b), instead of 16 h (c).
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cAMP by amplifying estrogen stimulated binding of the
receptor to p85aPI3K. H89 inhibited the binding of p85D
to estrogen receptor, indicating that another phosphor-
ylation PKA-dependent was necessary for the formation
of the complex estrogen-p85aPI3K.
These data indicate that phosphorylation by cAMP–
PKA of Ser 83 in p85aPI3K is required for estrogen
binding and signalling to PI3K.
Discussion
The data presented here indicate that the phosphoryla-
tion of p85aPI3K in a critical serine residue mediates
cAMP action on growth and survival. More specifically,
phosphorylation of Ser 83 in p85aPI3K shifts the signaling
flow towards PI3K-driven pathways. Such a conclusion
is supported by several observations. The substitution of
Ser 83 with alanine inhibited cAMP effects on cell
survival and G1 arrest in NIH 3T3 fibroblasts.
Conversely, the aspartic mutant of Ser 83 in p85aPI3K
stimulated cell survival in the absence of cAMP and
slowed down cell cycle cycle progression, replicating the
effects of cAMP. Ras binding to PI3K and AKT
phosphorylation were inhibited by expressing p85A
and were stimulated by p85D.
cAMP effects on growth and cell cycle progression are
very selective. cAMP–PKA act on at least three phases
E2 - + - + - + - + WB:p85 flag
p85
P-AKT
AKT
nt p85wt
p85wt p85A
IP: anti-p85 Ab
p85D
p85 flag
ERα
cAMP - - + + +
E2 - + - + +
H89 - - - - +
- - + + +
- + - + +
- - - - +
- + + +
- - + +
- - - +
p85A p85D
a
b
Figure 6 cAMP phosphorylation of p85aPI3K amplifies estrogen
binding and signaling to PI3K. MCF-7 cells were made quiescent
by charcoal-treated serum and medium lacking phenol-red for 3
days. (a) Quiescent cells were transfected with p85aPI3K wild type or
p85A or p85D. After 24 h, the cells were treated with 10 nM E2 for
3min. Cell lysates were analysed by Western blot with anti-p85aPI3K
(upper panel), P-AKT (middle panel) or AKT (lower panel). (b)
Quiescent cells were transfected with the wild type or the mutant
versions of p85aPI3K. After 24 h, the cells were treated with 10 nM E2
for 3min or for 10min with 200mM cAMP, or with 10 nM E2 for
3min following a 10-min stimulation with 200mM cAMP. The cell
lysates were immunoprecipitated with anti-flag antibody 15 h, as
described above. Sample aliquots were immunoblotted with anti-
ERa and anti-p85aPI3K antibodies to detect the PI3K/ER complex.
Lanes 5 and 14 show the complex estrogen receptor-p85aPI3K in
cells pretreated with 10 mM H89 for 30min.
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Figure 5 cAMP stimulates PI3K activity in the absence of serum. Effects of p85aPI3K mutants on PI3K catalytic activity. NIH3T3 cells
were transfected with the p85aPI3K expression vectors indicated and stimulated with cAMP (100 mM) 20min in the presence or absence
of H89 (10mM) or PDGF (100 ng/ml) 15min, 48 h after transfection. Total extracts were prepared and subjected to
immunoprecipitation with anti-flag antibody. Immunoprecipitates were quantified by immunoblot with anti-p85aPI3K antibodies
(p85aPI3K-flag) and assayed for PI3K activity by using a mixture of lipids containing PI4-5 (see Materials and methods). PI-4-5 labeled
at position 3 is indicated by the arrow. The upper inset (a) shows PI3K activity associated with p85aPI3K-flag wild type and the
immunoblot with anti-p85aPI3K antibody of the p85aPI3K-flag immunoprecipitate. The lower inset (b) shows PI3K activity associated
with p85A and p85D, immunoprecipitated with the anti-flag antibody. The immunoblot with the p85aPI3K antibody is shown below.
The histograms on the right show the statistical analysis of (a) and (b) derived from three experiments.
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of cell cycle. cAMP slows down G1, blocks S phase and
G2–M transition (Kato et al., 1994; Kurokawa and
Kato, 1998; Houslay and Kolch, 2000). Our data
indicate that p85aPI3K phosphorylation of Ser 83 controls
selectively G1–S transition (Figure 2).
PI3K is an important regulator of cell growth as it
links cell size, growth and cycle progression. For
example, constitutive expression of p110a increases cell
mass and size by stimulating the biosynthetic capacity of
the cells. However, if not restrained, p110 activity
impairs exit from the cell cycle (Alvarez et al., 2003).
We suggest that Ras–PI3K signals regulate the length of
G1 phase. cAMP by amplifying and stabilizing PI3K,
lengthens G1 and slows down G1–S transition. The net
result is an apparent G1–S block, which results in
increased biosynthetic activity and cell mass prior to
division. This is better shown in thyroid cells, FRTL5,
which are exquisitely dependent on TSH and cAMP for
growth and differentiation. In these cells, Ras and PI3K
are selectively required for G1 phase progression (Ciullo
et al., 2001). In thyroid cells, TSH induces PI3K activity
and stabilizes the complex Ras–PI3K. Also, expression
of p85 mutant (p85A) inhibits selectively the stimulation
of growth and PI3K activity induced by TSH (De
Gregorio et al., in press). In thyroid cells and in cells
expressing high levels of the regulatory subunit of PKA,
RIIb, p85aPI3K binds and anchors PKA. This binding is
amplified in cells expressing p85D and it is H89 resistant
(De Gregorio et al., in press). This suggests that
anchoring PKA to the membrane is a prerequisite for
cAMP–PKA biological effects.
Also, cAMP–PKA stimulate in the absence (Figure 5),
not in the presence of serum (Ciullo et al., 2001), PI3K
activity. This stimulation requires phosphorylation of
Ser 83 in in p85aPI3K, probably because phosphorylated
p85aPI3K induces a conformational change in the
p110aPI3K molecule (Supplementary Figure 1S) or
increases its affinity to PKA (De Gregorio et al., in
press). The stimulation of PI3K activity by cAMP
appears to be very selective, as p85A or p85D mutants
did not interfere with PDGF (Figure 4) or EGF (De
Gregorio et al., in press) induced PI3K activity.
Although the cell lines we have used are not robustly
dependent on cAMP signaling for growth or differentia-
tion, our data indicate that PI3K-Ras signals are
amplified by cAMP both in cAMP-independent
(NIH3T3 fibroblasts or breast MCF7 cells) or depen-
dent (thyroid) cells. In these latter cells, amplification of
PI3K by cAMP is mainly triggered by TSH and PKA,
which binds p85aPI3K. The amplification of the pathway
Ras–PI3K induced by cAMP is redundant in 3T3, but
not in thyroid cells, because in these latter cells
expression of p85A triggers apoptosis (De Gregorio
et al., in press).
We suggest that Ser 83 in p85aPI3K is an important
point of convergence of two parallel pathways: cAMP–
PKA and PI3K signals. In this framework, it is worth
noting that in Saccharomyces cerevisiae inactivation
of PI3K–TOR signalling is partly compensated by
iper-activation of cAMP–PKA (Rohde et al., 2004;
Zurita-Martinez and Cardenas, 2005).
Our data indicate that estrogen receptor signalling
was profoundly altered when p85A was expressed.
Accordingly, p85aPI3K binding to estrogen receptor was
severely impaired. Although PKA phosphorylates di-
rectly AKT and estrogen receptor (Cui et al., 2004), the
effects we described were mainly dependent on p85aPI3K,
as they were inhibited or amplified by expressing the
p85aPI3K alanine or aspartic mutants, respectively.
Moreover, we have data indicating that also induction
of estrogen responsive genes is inhibited by H89 and it is
significantly altered in p85A-expressing cells (data not
shown). Estrogens stimulate adenylyl cyclase (Aronica
et al., 1994) and cAMP–PKA stimulate differentiation
of granulosa cells (Knecht et al., 1984). Our data
indicate that phosphorylation of Ser 83 in p85aPI3K by
cAMP PKA stabilizes the binding of activated receptor
to PI3K and stimulates PI3K activity.
General implications
The data presented above have broad implications
because they point to p85aPI3K as the physical link
between Ras, estrogen receptor and cAMP–PKA
(Figure 7). Also, we find in many and unrelated cell
types that cAMP amplification of PI3K is essential for
negative or positive cAMP effects on growth and
survival. Apparently, all receptors binding p85aPI3K can
cooperate with cAMP–PKA signals via phosphorylation
of Ser 83 in p85aPI3K. This may explain the pleiotropic
nature of the effects exerted by cAMP–PKA on several,
apparently unrelated, signaling cascades and illustrates
how cAMP–PKA can influence Ras p21 effectors at
multiple levels.
Materials and methods
Plasmid construction
The cDNA encoding for p85aPI3K-flag wild type was generated
by fusing the flag sequence (MDYKDDDDK) to the C-
GPCR
ER
P p110
p85α
PKA
AKT
PKA
cAMP
cAMP
RAS
GTP
Figure 7 Amplification of estrogen and Gs protein-coupled
receptors (GPCR) signaling to PI3K. A scheme outlining the
effects of cAMP–PKA activation by Gs protein coupled receptors
on PI3K signaling by estrogens. PKA and cAMP arrows on the
right side indicate other cAMP–PKA targets that amplify Ras–
PI3K interaction. p85aPI3K links receptors coupled to G proteins to
estrogens and Ras–PI3K signals.
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Terminus of bovine p85aPI3K cDNA in the pSG5 vector (gift of
Dr J Downward). The region of p85aPI3K from the XhoI
restriction site in position 1014 (Acc. No: 163476) was
amplified by PCR with a 30 end primer containing the flag
sequence and a BamHI restriction site. The PCR product was
subcloned in the II-TOPO vector (Invitrogen), digested with
XhoI and BamHI, extracted and ligated to a pSG5-p85aPI3K
vector previously digested with the same restriction enzymes.
The vector encoding p85aPI3K-flag was then used as template
for site-directed mutagenesis (QuickChange Site-Directed
Mutagenesis Kit, Stratagene) to convert Ser 83 in alanine or
aspartic acid. All the plasmid constructs were verified by DNA
sequence analysis.
Cell culture and transfections
HeLa and NIH3T3 cells were grown in RPMI with 10% fetal
calf serum or Dulbecco’s modified Eagle’s medium (DMEM)
with 10% calf serum, respectively. MCF-7 cells were grown in
DMEM with 5% fetal bovine serum, supplemented with:
penicillin/streptomycin 100mU/ml, 2mM glutamine, 6 ng/ml
insulin and 3.75 ng/ml hydrocortisone. Cells were transfected
with lipofectamine (Gibco-Invitrogen, Carlsbad, CA, USA). In
all transfections, RSV-LacZ was included to determine and
normalize transfection efficiency. Experiments varying in the
transfection efficiency above 20% were discarded.
Antibodies, immunoprecipitation and immunoblot
The antibodies used were: anti-Ras (mouse monoclonal pan-
Ras clone 10, UBI (an affiliate of Millipore, Billerica, MA,
USA)), anti-p85PI3K (rabbit polyclonal, UBI), anti-P-Serine
(rabbit polyclonal, Zymed, San Francisco, CA, USA), anti-
Erk 1/2 (rabbit polyclonal, Santa Cruz, Santa Cruz, CA,
USA), anti-P-Erk 1/2 (mouse monoclonal, Santa Cruz), anti-
P-Akt Ser 473 (rabbit polyclonal, Cell Signaling, Beverly, MA,
USA), anti-Akt (rabbit polyclonal, Cell Signaling), anti-P-Gsk
Ser 21/9(rabbit polyclonal, Cell signaling), anti-GSKa/b
(mouse monoclonal, UBI). The anti-flag antibody was the
mouse monoclonal Sigma M2 antibody.
Immunoprecipitation
Total extracts were prepared by lysing the cells on ice 5min
with 50mM Tris-HCl pH 7.4, 1% Nonidet NP-40, 100mM
NaCl, 2mM EDTA 50mM NaF, 0.1mM NaVO3 1mM b-
glycerophosphate, 2.5mM sodium pyrophosphate and a
protease inhibitor cocktail. Cell lysates (2mg/ml) were
incubated with 4mg of antibody/0.5–1mg of protein at 41C
in gentle rock agitation 15 h. At the end of incubation, 20ml of
A/G plus were added to samples and the immunoprecipitates
were collected by centrifugation. SDS–PAGE and immuno-
blots were performed as previously described (Feliciello et al.,
2000).
Anoikis
At 48 h after transfection, the cells were collected and
maintained in suspension on dishes covered with a thin layer
of 2% agarose. Cells were plated in medium containing 0.1%
serum with or without 200mM CPT-cAMP (Sigma) for 5 h. At
the end of incubation, the cells were collected, washed twice
with phosphate-buffered saline (PBS) and incubated 5min
with propidium iodide and analysed by FACS.
Analysis of DNA content and 50-bromo-20-deoxyuridine (BrdU)
incorporation
2" 106 transfected cells (48 h after transfection) were plated in
100mm dishes and grown in low serum (0.5% fetal bovine
serum) for 18 h in the presence or in absence of 50mM 8-Cl
cAMP. Cells were labelled for 30min with BrdU to a final
concentration of 20mg/ml and harvested at 0, 90 and 270min.
After treatment, the cells were fixed in ice-cold 70% ethanol
for 4 h at þ 41C and washed three times in PBS. Cells were re-
suspended in 0.25ml of 1N HCl and maintained 20min at
room temperature. After acidic denaturation of DNA, the cells
were washed two times in phosphate/citric buffer (0.2M
Na2HPO4; pH 7.4). BrdU incorporation was revealed by
anti-BrdU-FITC (Becton Dickinson, Franklin Lakes, NJ
USA) and then stained for 30min at room temperature in
0.1% Triton X-100, 0.2mg/ml DNase-free RnaseA, 20 mg/ml
propidium iodide. Fluorescence was determined by using the
FACScan Flow Cytometer (Becton Dickinson). Experiments
were performed in triplicate. The data were acquired and
analysed by CELLQuest software (Becton Dickinson) and by
Cell Fit Cell-Cycle Analysis Version 2 for bivariate analysis of
DNA content versus BrdU incorporation.
In vitro phosphorylation
HeLa cells were transiently transfected with p85aPI3K-flag and
p85A. At 48 h after transfection, cell lysates were immunopre-
cipitated with non-immune IgG or anti-flag antibody 15 h at
41C. Protein A/G bound immunoprecipitates were washed
twice with lysis buffer and finally with kinase buffer (N-2-
hydroxyethylpiperazine-N0-2-ethane sulfonic acid (HEPES)
20mM, MgCl2 10mM, pH 7.4). The washed immunoprecipi-
tates were treated with 0.4 mg of partly purified catalytic
subunit of protein kinase A. Each aliquot was incubated in a
final volume of 30 ml of kinase buffer containing 10!5 M cAMP,
100 mM ATP and 10 mCi[g32P-ATP] for 30min at 301C. The
reaction was terminated by adding 2" Laemmli buffer.
Lipid kinase assay
Lipid kinase activity was determined as described by Maier
et al. (1999). Briefly, the assays were carried out in a final
volume of 50ml containing 0.1% bovine serum albumin, 1mM
EGTA (ethylene glycol-bis(b-aminoethyl ether)-N,N,N’,N’,-
tetraacetic acid), 120mM NaCl, 40mM HEPES, pH 7.4, 1mM
dithiothreitol, 1mM glycerophosphate, 7mMMgCl2 (buffer E).
Lipid vesicles (30 ml containing 320mM phosphatidylethanola-
mine, 300 mM phosphatidylserine, 140 mM phosphatidylcholine,
30 mM sphingomyelin, supplemented with 40mM PI-4,5-P2 in
buffer E) were sonicated 1 h and incubated on ice 10min. Some
aliquots were preincubated with LY294002, 0.5 mM (Calbio-
chem (EMD Biosciences, Inc, an Affiliate of Merck KGaA,
Darmstadt, Germany)) at 371C. The immunoprecipitates were
added to the lipid mixture and incubated for 10min at 41C in a
final volume of 40ml. The reaction was started by adding 40mM
ATP (1 mCi of [-32P]ATP in 10 ml of the assay buffer at 301C.
After 15min, the reaction was stopped with ice-cold 150ml
HCl (1 N) on ice. The lipids were extracted by vortexing the
samples with 500ml of chloroform/methanol (1:1). After
centrifugation the organic phase was washed twice with
200 ml of 1N HCl. Phosphorylated lipids were separated by
TLC, detected by autoradiography and quantified with
Phosphor-Imager.
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ORIGINAL ARTICLE
The p85 regulatory subunit of PI3K mediates TSH–cAMP–PKA growth
and survival signals
G De Gregorio1, A Coppa2, C Cosentino3, S Ucci1, S Messina1, A Nicolussi2, S D’Inzeo2,
A Di Pardo1, EV Avvedimento3 and A Porcellini1,2
1Dipartimento di Patologia Molecolare IRCCS Neuromed, Localita` Camerelle, Pozzilli, Italy; 2Dipartimento di Medicina
Sperimentale, Universita` ‘La Sapienza’, Viale Regina Elena, Roma, Italy and 31 Dipartimento di Biologia e Patologia Molecolare e
Cellulare, Istituto di Endocrinologia ed Oncologia Sperimentale del CNR, Universita` Federico II, Napoli, Italy
Phosphatidylinositol 3-kinase (PI3K) is necessary for
thyroid stimulating hormone (TSH)-induced cell cycle
progression. To determine the molecular mechanism
linking PI3K to TSH, we have identified a serine residue
in p85aPI3K phosphorylated by protein kinase A (PKA) in
vitro and in vivo. Expression of an alanine mutant (p85A)
abolished cyclic AMP/TSH-induced cell cycle progres-
sion and was lethal in thyroid cells (FRTL-5). The
aspartic version of the p85aPI3K (p85D) inhibited apoptosis
following TSH withdrawal. The p85aPI3K wild type not the
p85A bound PKA regulatory subunit RIIb in cells
stimulated with cAMP or TSH. The binding of the
aspartic version of p85aPI3K to RIIb was independent of
cAMP or TSH stimulation. Similarly, binding of PI3K to
p21Ras and activation of AKT, a downstream PI3K
target, were severely impaired in cells expressing the p85A
mutant. Finally, we found that the catalytic activity of
PI3K was stimulated by TSH in cells expressing the wild-
type p85aPI3K but not in cells expressing p85A. This latter
mutant did not affect the epidermal growth factor-
stimulated PI3K activity. We suggest that (1) TSH–
cAMP-induced PKA phosphorylates p85aPI3K at serine 83,
(2) phosphorylated p85aPI3K binds RIIb-PKA and targets
PKAII to the membrane, and (3) PI3K activity and
p21Ras binding to PI3K increase and activate PI3K
downstream targets. This pathway is essential for the
transmission of TSH–cAMP growth signals.
Oncogene advance online publication, 9 October 2006;
doi:10.1038/sj.onc.1210011
Keywords: phosphoinositide-3-kinase; signal trasduc-
tion; thyropropin receptor; protein kinase A; cAMP
Introduction
Stimulation of growth by cyclic AMP–protein kinase A
(cAMP–PKA) in selected cell types, as in thyroid cells, is
tightly dependent on Ras and Phosphatidylinositol 3-
kinase (PI3K) (Kupperman et al., 1993; Al-Alawi et al.,
1995; Miller et al., 1998). Also, cAMP–PKA are
powerful survival signals in all cell types tested (Affaitati
et al., 2003; Wang et al., 2005). To date, the mechan-
ism(s) and the relevant players mediating the effects of
on growth and survival are not completely known.
We have recently reported that growth of cells, NIH
3T3, normally inhibited by cAMP (Magnaldo et al.,
1989; Chen and Iyengar 1994), can be potently
stimulated by cAMP if the PKA subunit RIIb is
expressed in these cells (Porcellini et al., 2003). The
presence of RIIb in these lines amplified cAMP
survival and transcriptional signals. We have previously
shown that cAMP–PKA influence Ras signaling, by
selectively stimulating the Ras–PI3K complex. More-
over, p85aPI3K is an efficient PKA substrate in vitro
(Ciullo et al., 2001).
We have identified a serine (83) in the p85aPI3K
molecule that is phosphorylated in vivo and in vitro by
PKA. This phosphorylation mediates the interaction of
PI3K with p21Ras and estrogen receptor a (Cosentino
et al., 2006).
In this work, we describe the biological consequences
of the expression of mutant versions of p85aPI3K in
FRTL-5 thyroid cells and in an engineered NIH 3T3 cell
line that recapitulates the features of thyroid stimulating
hormone (TSH)-dependent growth of thyroid cells. Our
results demonstrate that phosphorylation of serine 83 is
critical for TSH-dependent cell cycle progression and
cell survival. Moreover, we found that phosphorylation
of serine 83 by cAMP–PKA was essential for binding of
p85aPI3K to the PKA regulatory subunit RIIb.
We conclude that, in the presence of the RIIb-PKA
subunit, abundant in cAMP-stimulated cells, p85aPI3K
enucleates a complex containing PKA. Phosphorylation
of serine 83 in the p85aPI3K molecule amplifies PKA
binding to PI3K and stimulates the Ras–PI3K complex,
which ultimately mediates survival and growth signals
induced by TSH–cAMP. This pathway is essential for
cAMP-dependent proliferation.
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Results
p85 phosphorylation mediates TSH-dependent cell cycle
progression and cell survival
Previous data from our laboratory have shown that the
p85aPI3K regulatory subunit can be phosphorylated by
PKA in vitro (Ciullo et al., 2001). Sequence analysis of
p85aPI3K revealed a putative PKA phosphorylation site,
which was conserved in mammalian p85aPI3K. To verify
that this sequence was a bona fide PKA site, we have
substituted this serine 83 by alanine (p85A) or aspartate
(p85D) to prevent or to mimic phosphorylation of
serine, respectively. The tagged wild-type recombinant
protein was phosphorylated in vivo and in vitro by PKA,
whereas p85A protein was not (Cosentino et al., 2006).
To test the biological effects of p85aPI3K phosphoryla-
tion on thyroid cell growth, we transfected the rat
thyroid cell line, FRTL-5, with p85WT, p85A and p85D
expression vectors. As we did not score a significant
number of stable transfectants expressing p85A, we
tested the plating efficiency of cells transfected with
p85A or p85D. Figure 1a shows that the expression of
p85A significantly reduced the number of clones of
FRTL-5 cells expressing p85A. Conversely, the number
of clones was significantly higher in cells expressing
p85D (Figure 1a). These data indicate that phosphor-
ylation of serine 83 in p85aPI3K significantly altered the
growth or survival of differentiated thyroid cells. To test
this notion in a defined experimental system, we used a
unique cellular model that recapitulates the features of
TSH-dependent growth and survival, that is, fibroblasts
coexpressing the PKA regulatory subunit RIIb and
wild-type TSHR under the control of an inducible
promoter (NTCRII). In this model, in the absence of
RIIb, activation of TSHR by TSH induced growth
arrest in the presence of serum. In the absence of serum,
these cells, stimulated with TSH, replicated their DNA
but underwent apoptosis. Coexpression of RIIb inhib-
ited apoptosis and stimulated the growth of the cells
only in the presence of TSH or cAMP (Porcellini et al.,
2003). We have expressed p85A or p85D in these cells
in the presence or absence of TSH or 8BrcAMP.
Figure 1b shows that cells expressing TSHR and
RIIb, which proliferated in the presence of TSH,
underwent apoptosis when starved of TSH. Expression
of p85WT slightly inhibited apoptosis. Expression
of p85D significantly reduced the fraction of apoptotic
cells starved of TSH. On the other hand, expression of
p85A significantly reduced the survival of these cells in
the presence of TSH. These data indicate that phos-
phorylation of serine 83 amplifies the transmission of
survival signals by TSH and PKA, and explain the low
survival rate of thyroid cells expressing p85A
(Figure 1a).
To analyse more precisely the biological effects of
p85A or p85D on cycle progression and growth of TSH–
RIIb-expressing cells, we carried out a detailed cell cycle
analysis by performing 5-bromodeoxyuridine (BrdU)
pulse–chase labeling experiments. In low serum, TSH
induced DNA synthesis and stimulated S and G2–M
transition in cells expressing p85WT or control plasmids
(Figure 1c). Expression of p85A resulted in a significant
accumulation of cells in S phase. Note that in 270min,
control cultures exit S phase and accumulated in G2M.
Expression of p85D did not significantly alter cell cycle
progression (Figure 1c). We have also tested if the
expression of p85A or p85D mutants altered cell cycle
progression or proliferation induced by epidermal
growth factor (EGF). Supplementary Figure 1S shows
that the growth rate and cell cycle progression induced
by EGF or serum (not shown) were not affected by the
expression of p85aPI3K mutants.
These experiments indicate that inhibition of phos-
phorylation of p85aPI3K at serine 83 slows down S–G2/M
progression induced by TSH–cAMP.
Phosphorylation of serine 83 in p85aPI3K is required for
TSH-induced AKT phosphorylation
As p85A inhibited cell cycle transitions induced by TSH,
we tested whether the signaling cascade triggered by
TSH or cAMP was impaired. cAMP and TSH
stimulated PKA, which can directly phosphorylate
AKT (Sable et al., 1997; Filippa et al., 1999) and/or
induce the recruitment of PI3K to the membrane (Suh
et al., 2003). We determined the phosphorylation of
AKT in cell lines expressing p85WT or p85 mutant in
the presence or absence of TSH. The ratio P-AKT/total
AKT, a rather accurate index of AKT activation, was
determined. Cells expressing p85WT, the p85A mutants
or p85D mutants were stimulated with TSH for various
periods of time and tested for AKT phosphorylation.
Figure 2 shows that TSH induced AKT phosphoryla-
tion and that in cells expressing p85A, AKT induction
was almost completely abolished. Both FRTL-5
(Figure 2a) and NTCRII cells (Figure 2b), expressing
p85A, were unable to activate AKT in the presence of
TSH. The expression of p85D did not significantly affect
the absolute level of AKT activation by TSH, but
modified the kinetics of activation in both cell lines
(Figure 2a and b). Induction of P-AKT by EGF was not
affected in cells expressing both mutants (Supplemen-
tary Figure 2S). Pretreatment with a PKA inhibitor H89
(10 mM) abolished TSH-induced AKT phosphorylation
(data not shown). These data indicate that serine 83 in
p85aPI3K is important for TSH induction of AKT.
Phosphorylation of serine 83 influences the formation of
PKA–PI3K and Ras–PI3K complexes
The p85A mutant induced apoptosis, inhibited cell cycle
progression and prevented AKT phosphorylation by
TSH in thyroid and NTCRII cells. Both cell lines were
exquisitely dependent on TSH and cAMP for growth.
As in these cells the expression of PKA subunit RIIb
conferred TSH- and cAMP-dependent growth (Porcelli-
ni et al., 2003), we tested whether p85aPI3K formed a
complex with RII-PKA. The RIIb–p85aPI3K complex
was assayed by a p85 pull-down assay, using the
glutathione S-transferase (GST)-RIIb fusion protein as
bait (Grieco et al., 1996). The binding assay was carried
out with extracts derived from NTCRII cells transiently
transfected with the p85WT, p85A, p85D or with the
p85 mediates TSH–PKA growth and survival signals
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empty vector (control) and from FRTL-5 clones stably
transfected with the same p85aPI3K vectors. FRTL-5 cells
were derived from the few clones expressing low levels of
p85A, as shown in Figure 1a.
Figure 3a shows that phosphorylated p85WT binds
the PKA type II regulatory subunit RIIb in a TSH-
dependent manner. TSH treatment (10mU/ml) for a
period of 10min induced the formation of the complex
Figure 1 Phosphorylation of serine 83 of p85 mediates TSH-induced cell cycle progression and cell survival. (a) Plating efficiency of
FRTL-5 cells expressing p85PI3K wild type, p85A or p85D. The ability to form G-418-resistant clones was determined by transfecting
FRTL-5 cells with expression vectors encoding p85PI3K wild type, the A mutant version (p85A) or the D mutant version (p85D) and
selecting the clones in the presence of 400mg/ml of G-418 for 15 days. Immunoblot analysis of duplicate plates indicated comparable
copy number of transfected p85PI3K. The histogram represents the number of colonies derived from 5! 105 transfected cells (mean of
three experiments in triplicate). (b) Apoptosis assay of NTCRII cells transfected with cytomegalovirus (CMV) (CTRL), p85WT, p85A
or p85D treated without (white bar) or with TSH (gray bar) or 8BrcAMP (black bar). Cells were transiently transfected with the
constructs indicated above. At 18 h after induction with 0.5% serum in the presence of TSH or cAMP, cells were subjected to TUNEL
assay as described in Materials and methods. Inset: Western blot analysis with anti-p85PI3K antibody to verify that expression of the
constructs was comparable in the different samples. (c) Cell cycle progression of cells expressing p85WT, p85A or p85D. NTCRII cells
were transiently transfected with the p85WT, p85A, p85D mutants or with the empty vector (control). At 24 h after transfection, the
cells were serum starved for 18 h and induced with 10mU/ml TSH in the presence of 0.5% serum. BrdU incorporation was assayed by
a pulse–chase experiment. Cells were labeled for 30min with BrdU and harvested at 0, 90 and 270min. Cells were subjected to
fluorescence-activated cell sorting (FACS) analysis for bivariate analysis of DNA content versus BrdU.
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Figure 2 Phosphorylation of serine 83 is required for TSH-induced AKT phosphorylation. Time course of TSH-induced AKT
phosphorylation in FRTL-5 (a) or NTCRII (b) cells expressing recombinant p85PI3K. Representative blots of extracts derived from
transiently transfected cells (NTCRII) or stable FRTL-5 clones (b) after 18 h of growth in 0.5% serum. TSH was added at a
concentration of 10mU/ml for the indicated time. The histogram in the lower panels shows the densitometric analysis of the P-AKT/
AKT ratio relative to b-actin and normalized to the transfection efficiency, derived from three independent experiments.
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in NTCRII (Figure 3a) or FRTL-5 (Figure 3b) cells
expressing recombinant p85WT. In contrast, in cells
expressing the p85A mutant, the formation of RIIb–
p85aPI3K complex was inhibited. The binding of p85aPI3K
to RIIb was observed after cAMP treatment (100 mM
8BrcAMP) (Figure 3c). Conversely, the p85D mutant
was bound to RIIb even in the absence of cAMP or TSH
(Figure 3a and c). We also detected bound p85aPI3K
phosphorylated at serine 83 with anti-phosphoserine
antibodies in p85WT, isolated from cells stimulated with
TSH (Figure 3a). Most notably, the binding of p85D to
RIIb was resistant to the PKA inhibitor H89 (Figure 3c)
and, as expected, it was not present in the immunoblot
probed with anti-phosphoserine antibody (Figure 3a).
To demonstrate a direct interaction of RIIb–p85aPI3K,
NIH 3T3 cells were transiently transfected with p85WT
or p85A and treated for 60min with 100 mM 8BrcAMP.
Exogenous p85aPI3K was immunoprecipitated with anti-
FLAG antibody, extensively washed in RIPA buffer
containing 1% Triton X-100"0.1% sodium dodecyl
sulfate (SDS) and purified by elution with 0.1M glycine
(pH 3.5). Purified p85aPI3K was then incubated in vitro
with GST-RIIb and a pull-down experiment was
repeated, as described above. Figure 4 shows that
p85WT binds GST-RIIb but not control GST. More-
over, the binding of p85aPI3K to RIIb was stimulated by
pretreating the cells with cAMP (Figure 4). The p85A
mutant did not bind RIIb, both in the presence and
absence of cAMP. Collectively, these data demonstrate
that p85aPI3K upon phosphorylation of serine 83 induced
by cAMP or TSH binds PKA via the regulatory subunit
RIIb. Proximity of PKA to PI3K may favor signaling of
both kinases to downstream effectors.
We have previously shown that cAMP–PKA selec-
tively increased the association between PI3K and
p21Ras (Ciullo et al., 2001). As this complex may
mediate the cytoprotective effects of cAMP–PI3K, we
set out to determine the formation of p21Ras–PI3K in
cells expressing wild type or the mutant versions of
p85aPI3K indicated above. NTCRII cells were transfected
with p85WT, p85A or p85D, and after 36 h, the cells
were serum starved for 16 h before treatment with TSH
for 10min. Cell lysates were immunoprecipitated with
anti-FLAG antibody and then analysed by Western blot
with anti-p85aPI3K and anti-Ras antibodies. In the
presence of TSH, p85aPI3K efficiently associated with
p21Ras in p85WT-expressing cells. This association was
greatly reduced in cells expressing p85A. In the absence
of TSH, Ras association with p85aPI3K was barely
detectable in p85WT- and p85A-expressing cells. Con-
versely, the association of the mutant p85D to p21Ras
was present in the absence of cAMP, but it was also
stimulated by cAMP (Figure 5). The same results were
obtained in FRTL–5-transfected clones (Figure 5).
We conclude that phosphorylation of p85aPI3K at
serine 83 by cAMP–PKA significantly stimulates the
interaction of PI3K with PKA and p21Ras. The p85aPI3K
Figure 3 Phosphorylation of serine 83 in p85PI3K selectively
influences the formation of PKA–PI3K complex. (a) p85PI3K–RIIb
complex formation in NTCRII cells. Pull-down experiment with
GST-RIIb challenged with extracts derived from NTCRII cells
transfected with p85WT, p85A and p85D and treated with 10mU/
ml TSH for 10min. RIIb binding proteins were probed with anti-
FLAG, anti-phosphoserine and anti-GST antibodies. (b) p85PI3K–
RIIb complex formation in FRTL-5 cells. The same pull-down
experiment described in (a) was carried out with extracts of stable
transfected FRTL-5 cells. (c) p85PI3K binds RIIb in a cAMP-
dependent manner in NTCRII cells. Immunoblot analysis of
p85PI3K bound to RIIb in transiently transfected NTCRII cells.
Cells were starved of serum for 6 h (0.5% serum) and exposed to
100mM 8BrcAMP for 15min with and without 10 mM H89.
Figure 4 Purified p85 binds RIIb in vitro. Exogenous p85PI3K was
immunoprecipitated with anti-FLAG antibody from NTCRII cells
transfected with p85WT or p85A, and exposed to 100mM
8BrcAMP for 15min. The immunoprecipitate was extensively
washed in RIPA buffer containing 1% Triton X-100 "0.1% SDS
and purified by elution with 0.1M glycine pH 3.5. Input indicates
the eluted fraction; (þ ) glycine represents the pellet after elution.
The purified p85PI3K was incubated in vitro with GST-RIIb in a
pull-down experiment as described in Materials and methods.
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mutant, p85A, inhibited these interactions and down-
stream PI3K signaling, such as AKT phosphorylation.
To test if phosphorylation of serine 83 in p85aPI3K
influenced the catalytic activity of PI3K, we performed
PI3K enzymatic assays on immunoprecipitated p85aPI3K.
Figure 6 shows that TSH stimulated PI3K activity,
although less efficiently than EGF, and that p85A
inhibited TSH induction. To test if p85A inhibited PI3K
activity per se, independent of the specific signaling
pathway involved, we tested EGF-induced PI3K in cells
expressing p85A or p85D. Figure 6B shows that PI3K
activity induced by EGF was sensitive to the specific
PI3K inhibitor LY294002 and that expression of p85A
or p85D did not influence EGF-induced activity.
These data indicate that phosphorylation of serine 83
in p85aPI3K selectively influences TSH- or cAMP-induced
PI3K activity.
Discussion
The data presented demonstrate the importance of
p85PI3K in the transmission of TSH and cAMP growth
and survival signals. Specifically, phosphorylation of
serine 83 in the p85aPI3K is essential for the binding of
PI3K to PKA. We suggest that following PKA
anchoring to PI3K, p21Ras associates to the complex
and PI3K catalytic activity is greatly stimulated.
Mutagenesis of this site profoundly and selectively
impaired the transmission of TSH signals by disrupting
this complex. EGF (Supplementary Figure 2S and
Figure 6) or PDGF stimulation of PI3K (Cosentino
et al., 2006) was not influenced by the substitution of
serine 83 by alanine or aspartate in p85aPI3K. The
stimulation of PI3K catalytic activity by cAMP–TSH
was evident in the absence of serum (see also, Porcellini
et al., 2003) and was dependent on the phosphorylation
of serine 83 in p85aPI3K. However, the aspartic mutant of
serine 83 p85aPI3K replicated cAMP effects on (i) the
inhibition of apoptosis by TSH starvation and (ii) the
binding to PKA. It amplified cAMP effects on (i) PI3K
activity, (ii) AKT phosphorylation and (iii) the efficiency
of formation of the complex PI3K–p21Ras. These data
indicate that serine 83 phosphorylation of p85aPI3K is
necessary but not sufficient to stimulate PI3K, phos-
phorylation of AKT and formation of the p21Ras–PI3K
complex. Functional PKA is indeed required for these
cAMP effects. As PKA binding to p85D is H89-resistant
(Figure 3c), phosphorylation of serine 83 in p85aPI3K is
necessary and sufficient for PKA anchoring to PI3K.
This is a non-redundant circuit in thyroid or cells
expressing TSHR and PKAIIb, because its elimination
profoundly impaired survival and growth. In contrast,
in cells containing low levels of cAMP and RIIb, the
expression of p85A abolished only cAMP response,
with a marginal effect on survival (data not shown;
Cosentino et al., 2006). As for the mechanism, the data
presented indicate that the serine 83 in p85aPI3K is a
critical site for the transmission of receptor signals to
PI3K. The alanine mutant inhibits cAMP effects on
PI3K activity. It is possible that a conformational
change induced by phosphorylation is important for
stimulation of PI3K activity. It is noteworthy that
substitution of serine 83 by aspartate in p85aPI3K
stabilizes the complex with p110 (Cosentino et al., 2006).
We wish to stress that these data highlight a general
role of serine 83 in the p85aPI3K molecule in the
transmission of cAMP signals in many cell types. We
have recently found that many independent signaling
pathways that stimulate cAMP converge on this site.
For example, p85A disrupts the binding of PI3K to
estrogen receptor and inhibits AKT activation by
estrogens (Cosentino et al., 2006).
We suggest that phosphorylation of serine 83 by
cAMP–PKA induces a conformational change in the
PI3K complex, resulting in facilitated binding to
receptors and to p21Ras, with stimulation of PI3K
activity. We believe that this site is a nodal point where
information from several receptors is channeled to
PI3K.
Materials and methods
Materials and reagents
Unless otherwise specified, drugs and chemicals were obtained
from Sigma Aldrich (St Louis, MO, USA) and cell culture
supplies were purchased from standard suppliers, for example,
Falcon, BD Biosciences, San Jose, CA, USA; GIBCO-Life
Figure 5 Phosphorylation of serine 83 selectively influences the formation of Ras–PI3K complex. The p21Ras–p85aPI3K complex was
assayed by immunoprecipitation with anti-FLAG antibodies and immunoblotting with anti-pan-Ras antibodies. NTCRII cells were
transiently transfected with p85WT, p85A, p85D or with the empty vector. FRTL-5 cells were the stable clones indicated in Figure 1.
Cells were starved of serum for 6 h (0.5% serum) and exposed to 10mU/ml TSH for 20min.
p85 mediates TSH–PKA growth and survival signals
G De Gregorio et al
6
Oncogene
Figure 6 Selective stimulation of PI3K activity by TSH. (A) (a) A representative autoradiogram of the TSH-induced lipid kinase
assay. NTCRII cells were transfected with p85aPI3K expression vectors as indicated in Figure 1. At 48 h after transfection, cells were
serum starved and maintained in low serum (0.2%) for 8 h. Cells were treated with TSH (10mU/ml) or EGF (100 ng/ml) for 20min.
p85-FLAG was immunoprecipitated (IP) with the anti-FLAGM1 affinity gel and the immune complexes were subjected to PI3K lipid
kinase assays as described in Materials and methods. (b) Immunoblot analysis indicated comparable amounts of immunoprecipitated
p85-FLAG. (c) The histogram shows the densitometric analysis normalized to the IP efficiency derived from three independent
experiments. (B) (a) A representative autoradiogram of the EGF-induced lipid kinase assay on anti-FLAG and anti-p85aPI3K IP
samples. The right-hand panel shows the PI3K activity derived from cells stimulated with EGF in the absence or presence of the
specific PI3K inhibitor LY294002. (b) Densitometric analysis normalized to the IP efficiency from three independent experiments.
(c) Immunoblot analysis indicated comparable amounts of immunoprecipitated p85aPI3K.
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Technologies, Invitrogen S.R.L, San Giuliano Milanese (MI),
Italy, HyClone, Logan, UT, USA.
Cell lines
Mouse fibroblasts NIH 3T3 were grown in Dulbecco’s
modified Eagle’s medium containing 10% fetal calf serum
and 2mM glutamine (standard medium). The tTA repressor-
expressing clones were grown in standard medium containing
puromycin 2.5mg/ml puromycin, 1.0 mg/ml tetracycline and
200 mg/ml geneticin (G-418). The selection and tetracycline
were removed 48 h before starting the experimental procedures
described below. The FRTL-5 cell line is a thyroid cell line,
which has been extensively characterized with respect to
thyroglobulin expression and TSH-dependent growth (Ambe-
si-Impiombato et al., 1980). Cells were grown in F12 medium
with 5% calf serum and six hormones (1mU/ml TSH, 1 mg/ml
insulin, 3.6 mg/ml hydrocortisone, 5 mg/ml transferrin, 10 ng/ml
somatostatin, 20 mg/ml glycyl-histidyl-lysine). FRTL-5 clone
expressing the p85 variants was generated by transfecting
FRTL-5 cells with the pSG5-p85 vectors. Neomycin-resistant
clones were isolated and characterized for NEO and p85
expression by Western blots.
Plasmid construction
The p85aPI3K plasmids have been described by Cosentino et al.
(2006). Briefly, p85 cDNA was subcloned in pSG5 vector.
FLAG sequence was added by subcloning into the XhoI/
BamHI sites of the pSG5-p85 vector a PCR fragment spanning
from the XhoI site of p85PI3K at position 1014 to the end of the
fragment. The vector encoding for p85-FLAG was then used
as a template of PCR for site-directed mutagenesis (Quick-
Change Site-Directed Mutagenesis Kit, Stratagene, Cedar
Creek, TX, USA) to convert serine 83 to alanine.
Transfections
The day before transfection, cells were plated at 60%
confluence in 100mm dishes and transfected with 2 (NTCRII)
or 8 (FRTL-5)mg/dish of p85WT, p85A, p85D or empty
vector using 2.75 or 12.5 ml/mg DNA of Lipofectamine Plus
(Invitrogen, Carlsbad, CA, USA). Following 5 h of exposure
to lipofectamine, the cells were washed and grown for 36–48 h
before assays.
Cell growth analysis
Proliferation was analysed under different conditions: normal
medium or low serum (0.5%) with and without 10mU/ml TSH
or 25 ng/ml EGF. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyl tetrazolium bromide) colorimetric assay for prolifera-
tion was performed in a 96-well flat-bottomed tissue culture
tray for each time point: 1500 cells for each clone were seeded
in eight replicas for each experimental point; 6 h after plating,
the standard medium was removed and 100 ml of culture
medium with stimuli as indicated was applied. The determina-
tions were carried out every 24 h as follows: 0.01ml MTT stock
(5mg/ml) was added to each well, then after 4 h of incubation
at 371C, the medium was removed and 0.1ml isopropanol/
0.04 N HCl was added. The absorbance was measured after 1 h
on an enzyme-linked immunosorbent assay plate reader. We
have used a Dynatech MR580 reader with a test wavelength of
570 nm and a reference wavelength of 630 nm.
Western blot
Cells were transfected as indicated above. After 48 h, cells were
exposed to 10mU/ml TSH, 100 mM 8BrcAMP or 100 ng/ml
EGF, harvested at times indicated and lysed on ice-cold RIPA
buffer (1% Triton X-100, 0.5% sodium deoxycholate (DOC),
0.1% SDS, 50mM Tris-HCl pH 7.6, 150mM NaCl, 1mM
phenylmethylsulfonyl fluoride, 1mg/ml aprotinin, leupeptin
and pepstatin). After centrifugation at 12 000 g, protein
concentrations were determined. Fifty micrograms of
protein was subjected to 7 or 12% SDS–polyacrylamide gel
electrophoresis and transferred onto nitrocellulose membranes
(Schleicher and Schuell, Whatman plc, Brentford, Middlesex,
UK, Germany). Western blot analysis was carried out by using
the appropriate antibody as noted in the figures. The anti-p85
was from Upstate-Millipore (Billerica, MA, USA) (#06-497).
The anti-pan-Ras antibody was from Calbiochem (affiliate of
Merck KGaA, Darmstadt, Germany) (EMD Biosciences Inc.,
an affiliate of Merck KGaA, Darmstadt, Germany). The
antibody against Akt and phospho-Akt were from Cell
Signaling Technology (Beverly, MA, USA). The horseradish
peroxidase-conjugated anti-rabbit and anti-mouse secondary
antibodies and the ECL detection system were from Amer-
sham Pharmacia Biotech Italia (Milano, Italy).
Pull-down and immunoprecipitation
Cells were lysed in pull-down buffer (200mM NaCl, 50mM
Tris-HCl pH 7.5, 2mM MgCl2, 10% glycerol, 1% NP-40,
10 mg/ml trypsin inhibitor, 1 mg/ml aprotinin, 1mg/ml leupep-
tin, 10mM NaF, 10mM Na3VO4). The cell extracts (1mg) were
incubated with 1 mg of GST-HRIIb fusion protein for 4 h at
41C with gentle rock agitation. The pellets were washed in pull-
down buffer and processed for Western blot analysis as
described.
Total extracts for immunoprecipitation were prepared by
incubating cells on ice with RIPA buffer containing 1mM
ethylene diaminetetraacetic acid. Cell lysates (1mg) were
incubated with 2mg of normal mouse IgG (sc 2025) and 25ml
of protein A Sepharose (Amersham Pharmacia Biotech,
Piscataway, NJ, USA) for 1 h at 41C. After centrifugation,
protein lysates were incubated with 4mg of anti-FLAG M1
affinity gel (Sigma A4596) for 4 h at 41C on a rocking plate.
The pellets were washed with RIPA buffer and processed for
Western blot analysis as already described. The fusion protein
was eluted by using 0.1M glycine HCl pH 3.5 and neutralized
with 1M Tris-HCl pH 8.
Analysis of DNA content and BrdU incorporation
Cell cycle analysis was carried out by fluorocytometric
absorbent cell sorter (FACS): 5! 105 transfected cells (48 h
after transfection) were plated in 60mm dishes and grown in
low-serum medium (0.5% fetal bovine serum) for 18 h and
induced into the cell cycle with 0.5% serum in the presence of
10mU/ml TSH or 100 ng/ml EGF. BrdU incorporation was
assayed in a pulse–chase experiment. Cells were labeled for
30min with BrdU to a final concentration of 20 mg/ml and
harvested at 0, 90 and 270min. After treatment, cells were
fixed in 70% ice-cold ethanol for 4 h at 41C and washed three
times in phosphate-buffered saline (PBS). Cell pellet was
resuspended in 0.25ml of 1N HCl and let to stand for 20min
at room temperature (RT). After acidic denaturation of DNA,
cells were washed two times in phosphate/citric buffer (0.2M
Na2HPO4, pH 7.4). BrdU incorporation was revealed by anti-
BrdU-FITC (Becton Dickinson, Franklin Lakes, NJ, USA)
and then stained for 30min at RT in 0.1% Triton X-100,
0.2mg/ml DNase-free RNaseA and 20mg/ml propidium
iodide. Fluorescence was determined by using the FACScan
Flow Cytometer (Becton Dickinson). Experiments were
performed in triplicate. The data were acquired and analysed
by CELLQuest software (Becton Dickinson) for bivariate
analysis of DNA content versus BrdU and by Cell Fit Cell-
Cycle Analysis Version 2 for DNA content analysis.
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Apoptosis assay
5! 105 cells were grown in 60mm dishes. At 18 h after
treatment, cells were fixed in 2% paraformaldehyde/1! PBS
for 10min at RT and washed once in PBSþ 50mM glycine for
10min at RT and washed again three times for 5min in PBS.
Cells were permeabilized with 0.5% Triton X-100/1! PBS for
10min, washed 3! 5min in PBS and incubated with 100 ml of
1!TdT reaction mix. TdT-mediated dNTP nick end labeling
was carried out at 371C for 60min using 15U of TdT (Roche
Diagnostics S.p.A, Roche Applied Science, Monza, Italy) and
2ml of 2mM BrdUTP. BrdUTP incorporation was revealed by
anti-BrdU-FITC and then stained with propidium iodide. The
data were acquired and analysed by CELLQuest software for
bivariate analysis of DNA content versus BrdU. Experiments
were performed in triplicate.
Lipid kinase assay
Lipid kinase activity was determined as described by Maier
et al. (1999). Briefly, the assays were carried out in a final
volume of 50 ml containing 0.1% bovine serum albumin, 1mM
ethylene glycol-bis (b-aminoethylether) tetraacetic acid,
120mM NaCl, 40mM HEPES, pH 7.4, 1mM dithiothreitol,
1mM glycerophosphate and 7mM MgCl2 (buffer E). Lipid
vesicles (30 ml containing 320 mM phosphatidylethanolamine,
300mM phosphatidylserine, 140 mM phosphatidylcholine and
30mM sphingomyelin, supplemented with 40 mM L-a-Phospha-
tidylinositol-4,5-bisphosphate (PI-4,5-P2) in buffer E) were
sonicated for 1 h and incubated on ice for 10min. Some
aliquots were preincubated with 0.5 mM LY294002 (Calbio-
chem) at 371C. The immunoprecipitates were added to the
lipid mixture and incubated for 10min at 41C in a final volume
of 40ml. The reaction was started by adding 40mM ATP (1 mCi
of [32P]ATP in 10 ml of the assay buffer (301C)). After 15min,
the reaction was stopped with ice-cold 150ml of 1 N HCl on ice.
The lipids were extracted by vortexing the samples with 500 ml
of chloroform/methanol (1:1). After centrifugation, the or-
ganic phase was washed twice with 200ml of 1N HCl.
Phosphorylated lipids were separated on a potassium oxa-
late-pretreated thin-layer chromatography plates (silica gel 60
Merck) developed in CHCl3/CH3OH/H2O/NH4OH
(60:47:11.3:2), dried, and visualized by autoradiography and
quantified with Phosphor-Imager.
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